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ABBREVIATIONS 
API active pharmaceutical ingredient 
ATR-FTIR attenuated total reflection Fourier transform infrared 
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LLC-GEN genistein-containing lyotropic liquid crystal  
MCR-ALS multivariate curve resolution – alternating least squares  
PBS phosphate buffer solution 
Q cumulative amount of API diffused/penetrated per cm
2
 
R
2 
determination coefficient 
SC stratum corneum 
SD standard deviation  
SE sucrose fatty acid ester 
SEM standard error of the mean  
Skin PAMPA skin parallel artificial membrane permeability assays  
SL sucrose laurate  
SLS sodium lauryl sulfate 
SM sucrose myristate 
TEWL transepidermal waterloss 
TR Transcutol 
XYL xylitol 
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1. INTRODUCTION  
Great attention is currently paid to skin care and skin disease prevention. Physical and 
psychological health are affected to considerable extents by the integrity of the skin. An 
appropriate skin condition is therefore essential for healthy skin. 
From a pharmaceutical industrial standpoint, the skin is a desirable target for drug 
delivery. The first transdermal drug was approved by the US Food and Drug Administration 
over 35 years ago. Today, transdermal products represent a growing, multibillion dollar 
market. The US transdermal drug delivery market approached $1.2 billion in 2001, $6.7 
billion in 2006 and nearly $7.9 billion in 2010.  By 2015, the global transdermal market is 
expected to reach $32 billion (Walter et al., 2015).  
Not surprisingly, transdermal drug delivery has received increased attention in recent 
years thanks to its numerous advantages over the oral and injection routes, such as avoidance 
of the hepatic “first-pass” metabolism, sustained drug delivery, protection of the 
gastrointestinal tract from drugs and good patient compliance. Unfortunately, the number of 
drugs which can be administered by this route is limited. Increase of the number of 
transdermally applied drugs and the optimization of drug delivery through the human skin are 
therefore important research opportunities in modern therapy.  Ideal transdermal drug delivery 
systems must be designed to overcome the skin barrier and deliver a therapeutically effective 
amount of drug through the skin, while skin barrier repair must be facilitated and a good skin 
condition ensured.  
In order to enhance transdermal drug absorption, different methodologies have been 
investigated and developed. Improvements in physical penetration enhancement technology 
have led to renewed interest in transdermal drug delivery. Some of these novel advanced 
transdermal penetration enhancement techniques include iontophoresis, electroporation (EP), 
ultrasound, microneedles to open up the skin, and more recently the use of transdermal 
nanocarriers.  
More complex drug–device combinations are being developed to overcome the natural 
barrier function of the skin. From a pharmaceutical technological viewpoint, it is an 
interesting task to investigate the new transdermal drug delivery techniques, in the interest of 
the optimization and development of these strategies.  
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2. LITERATURE BACKGROUND 
2.1. Skin structure and barrier function 
The skin, which forms the barrier between the body and the environment, is the largest 
organ of the body with a surface area of 2 m
2
; it accounts for about 16% of the body weight. It 
consists of three main layers: the epidermis, the dermis and the subcutaneous layer (Fig. 1).  
Figure 1. Sectional view of the skin (MacNeil, 2007). 
The epidermis is the 0.05–1.5 mm thick external layer, which serves as the physical and 
chemical barrier between the interior body and the exterior environment (Fig. 2).  It is mainly 
composed of keratinocytes (about 90%), but also contains melanocytes (about 8%), 
Langerhans cells and Merkel cells (Tortora et al., 2014). It consists of five major layers, but 
the main penetration barrier for most drugs is the stratum corneum (SC), the outermost 10–15 
µm thick zone of the epidermis (Barry, 1983). The SC consists of several layers of almost 
nonpermeable, nonviable cornified cells (corneocytes) embedded in an intercellular matrix of 
lipids. These lipids comprise approximately 50% ceramides, 25% cholesterol, 15% free fatty 
acids and some minor components (Prausnitz et al., 2012).  
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Figure 2. Sectional view of the epidermal layers. The clear layer (not shown) is found only in 
the very thick epidermis of the palms and soles (Wickett et al., 2006). 
The dermis, which is 3–5 mm thick, is composed of connective tissue containing 
collagen and elastic fibers. It is situated below the epidermis and contains sweat glands, hair 
roots, nerve cells, fibers, and blood and lymph vessels. Its main functions are the regulation of 
body temperature, the supply of oxygen and nutrients to the skin, and the removal of toxic 
products.  
The subcutaneous layer (hypodermis) is not part of the skin but, as one of its functions, 
it attaches the skin to the underlying tissues and organs. It is made up of loose connective 
tissue and fat, which can be up to 3 cm thick on the abdomen (Tortora et al., 2014). 
The SC protective barrier may undergo disorganization as a result of several skin 
diseases (such as atopic dermatitis, psoriasis and contact dermatitis), environmental or 
intrinsic factors, psychological stress and aging (Grice, 1980; Ghadially et al., 1995; Denda et 
al., 1998; Denda et al., 2000). The skin condition affects the overall confidence of the 
majority of people.  At a global level, skin conditions are the fourth leading cause of nonfatal 
diseases. Skin disease prevention and the development of a targeted dermal system which 
ensures individual patient treatment are therefore needed to prevent human skin problems in 
the world today (Fig. 3) (Hay et al., 2014).  
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Figure 3. Disability-adjusted life year rate per 100,000 individuals in 2010 (all skin 
conditions combined) (Hay et al., 2014). 
Psoriasis, one of the most common chronic inﬂammatory skin diseases, with a 
frequency of approximately 1-2% of the population in the developed world, is characterized 
by regular exacerbations of cutaneous symptoms and frequent articular involvement. The 
diagnosis is usually made on clinical grounds, though rarely a skin biopsy is necessary. The 
disease has a polygenic inheritance, and the expression of the symptoms is greatly influenced 
by environmental factors, such as stress or streptococcal infections (Schön et al., 2005; 
Bernard et al., 2007). 
Histologically, the disease is characterized by keratinocyte hyperproliferation, 
lymphocyte and granulocyte infiltration of the epidermis and dermis, and vasodilation of the 
dermal blood vessels. It is well known that multiple lipid bilayers play an important role in the 
permeability of the skin, and psoriatic skin is more permeable than healthy skin (Bernard et 
al., 2007). A number of studies have demonstrated that psoriatic skin exhibits alterations in 
lipid metabolism (Motta et al., 1994; Holtje et al., 2001), whereas the changes in the proteins 
and their conformations in the SC of psoriatic skin have not been well studied to date. 
2.2. Drug penetration through the skin 
Increasing the transdermal delivery of the drug through the skin is a challenging 
obstacle because very few drugs fit the criteria. The best candidate drug for transdermal 
delivery has the following properties (Guy, 1996; Finnin et al., 1999; Bos et al., 2000; 
Benson, 2005):  
 molecular weight < 500 Da, 
 melting point < 200 °C, 
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 log P octanol/water between 1 and 4, 
 a dose < 50 mg per day, and ideally < 10 mg per day, 
 ≤ 2 hydrogen-bonding groups, 
 not an irritant to the skin, 
 and does not stimulate an immune reaction in the skin. 
The three potential pathways by which drugs can cross the SC are the intercellular, 
transcellular and transappendageal routes (Fig. 4). The intercellular route is the predominant 
penetration pathway of drug molecules under normal circumstances. In this pathway, the drug 
overcomes the SC by passing between the corneocytes. This route involves sequential 
diffusion and partitioning between the polar head groups and the alkyl chains of the 
intercellular lipids, and the diffusional path length is therefore much longer than the simple 
thickness of the SC and has been estimated as long as 500 µm (Hadgraft, 2004). 
Figure 4. Different transport pathways through the SC (Lane, 2013). 
The shortest route for drugs is the transcellular pathway. This is a direct route where the 
drug has to cross the skin by directly passing through both the lipid structures of the SC and 
the cytoplasm of the dead keratinocytes. However, drugs resist penetration because they have 
to cross both lipophilic and hydrophilic structures (Trommer et al., 2006). 
The transappendageal route is considered to be minor (Moser et al., 2001) because 
sweat glands and hair follicles occupy only 0.1% of the total surface area of the human skin 
(Scheuplein, 1967). However, the hair follicles have been shown to be a relevant penetration 
pathway for particles and also an important long-term reservoir (Lademann et al., 2011). 
Furthermore, iontophoretic drug delivery uses an electrical charge to drive molecules into the 
skin primarily via the transappendageal route as this provides less electrical resistance 
(Benson, 2005). 
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2.3. Transdermal drug delivery strategies 
2.3.1. Passive methods  
The conventional means of applying drugs to the skin include vehicles such as 
ointments, creams, gels and patch technology. Such dosage forms have recently been 
developed and/or modified to enhance the driving force of drug diffusion (thermodynamic 
activity) and/or increase the permeability of the skin. The passive strategies most widely 
applied with the aim of improving drug penetration involve the skin hydration and the use of 
chemical penetration enhancers (CPEs). Increased tissue hydration tends to increase skin 
penetration and is the safest method through which to increase the transdermal delivery of 
both hydrophilic and lipophilic compounds. The ideal semisolid dermal drug delivery system 
should moisturize the skin well in order to enhance drug penetration (Barry, 2001).  
More than 360 CPEs have been demonstrated to enhance the skin permeability 
(Karande et al., 2005). Their mechanisms of action involve disruption of the intercellular 
lipids of the highly ordered SC, or interaction with intracellular proteins, or improvement of 
the drug partition into the SC (Garg et al., 2013).  
The ideal CPE should be nonirritating, nontoxic and nonallergenic, should have rapid, 
unidirectional working with predictable duration and have no pharmacological activity, and 
should be compatible with both excipients and drugs. Not surprisingly, to date only few have 
been routinely incorporated in the currently marketed transdermal products (Williams et al., 
2004). Investigations of the efficacy of CPEs are therefore highlighted that will promote the 
rational selection of CPEs and ultimately the development of safer and more efficacious 
formulations. Table 1 summarizes the classification of CPEs based on the chemical class to 
which the compounds belong.  
Transcutol (TR) and sucrose esters (SEs) are biocompatible CPEs.  TR is a powerful 
solubilizing agent that enhances the percutaneous penetration of various drugs, especially 
when it is used in combination with suitable surfactants (Touitou et al., 1994; Cázares-
Delgadillo et al., 2005). 
SEs, a new generation of nonionic surfactants, are likewise favorable CPEs. They 
consist of a sugar substituent, sucrose as the hydrophilic group and a fatty acid as the 
lipophilic group (Mitsubishi-Kagaku Foods Co., 1982). These natural compounds possess 
many advantages, such as low toxicity, good biocompatibility and excellent biodegradability 
(Kanikkannan et al., 2002; Youan et al., 2003). Ionic surfactants (e.g. sodium lauryl sulfate, 
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SLS) are generally more potent CPEs than their nonionic counterparts, but these agents can 
damage the barrier of the skin if applied for a long time. SEs, which cause less dermatological 
damage, act by altering the ordered structure of the intercellular region of the SC (Csóka et 
al., 2007). Their hydrophilic-lipophilic balance (HLB) value ranges from 1 to 16 (Ganem-
Quintanar et al., 1998). SEs are widely used in the food and cosmetic industries and have 
recently received increased attention in the pharmaceutical field (Szűts et al., 2012).   
Glycerol (GLY), which is also applied in several external formulations, hydrates the 
skin because it acts as a humectant (Rawlings et al., 2004; Andersen et al., 2007). Moreover, it 
improves the barrier function, exerts an anti-irritant effect, stabilizes the skin collagen and 
accelerates wound healing (Fluhr et al., 1999; Fluhr et al., 2008). Xylitol (XYL) is a naturally 
occurring polyol, which is a widely used substitute of sugar. Recent studies indicated that 
XYL can also be utilized as a humectant and moisturizer (Cohen et al., 1993; Leite e Silva et 
al., 2009).  
Table 1. The classification of CPEs (Marwah et al., 2015). 
 
 
 
Chemical class                                                                               Compounds 
  
 
Water                                                                                                              Water 
Hydrocarbons                                                          Alkanes, Alkenes, Squalene, Mineral oil, Halogens 
Alcohols                                                            Glycerols, Glycols, Polyglycols, Ethanol, Caprylic alcohol 
Acids                                                                           Oleic acid, Undecanoic acid and other fatty acids 
Amines                                                            Primary, secondary and tertiary, cyclic and acyclic amines 
Amides                                            Pyrrolidone(N-methyl-2-pyrrolidone, 2-pyrrolidon), azones (Azone) 
                                                                                                        (1-dodecylazacycloheptan-2- one)), Urea  
Ethers                                                                                    Diethylene glycol monoethyl ether (Transcutol) 
Esters                                                                                  Isopropyl myristate, Sucrose fatty acid esters 
Surfactants                                                                              Sodium lauryl sulfate, Cetyltrimethyl ammonium 
 (anionic, cationic, non-ionic, Zwitterionic)                             bromide, Sorbitan monolaurate, Polysorbate 80,  
                                                                                                          Dodecyl dimethyl ammoniopropane sulfate 
Terpenes, terpenoids and essential oils                                                              Menthol, Limonene 
Sulfoxides                                                                               Dimethyl sulfoxide, Dodecyl methyl sulfoxide 
Lipids                                                                                                              Phospholipids 
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Another convenient method of increasing drug transport across the skin is the use of 
carrier formulations as skin delivery systems. In this respect, an interesting possibility is 
offered by lyotropic liquid crystals (LLCs). They are characterized by the properties of both 
liquids and solids, i.e. they exhibit in part a structure typical of fluids and also the structured, 
crystalline state of solids (Tadwee et al., 2012). LLCs are usually formed from water and one 
or two surfactants and possibly cosurfactants and oils. The advantageous qualities of such 
formulations include their amphiphilic nature, the similarity to colloidal systems existing in 
living organisms, the various structures of liquid crystal states, and their thermodynamic 
stability (Makai et al., 2003; Vicentini et al., 2007). LLCs display good solubilizing effects 
and the sustained release and enhanced bioavailability of other lipophilic drugs (Boyd et al., 
2006). 
Other passive possibilities are outlined in Table 2. However, the amounts of drugs that 
can be delivered by these methods are limited because the barrier properties of the skin are 
not fundamentally changed, which has led to studies involving alternative strategies, referred 
to as active methods. 
Table 2.  Passive transdermal drug delivery strategies (Barry, 2001). 
2.3.2. Active methods 
These strategies have been shown to deliver macromolecules (> 500 Da, polar or apolar 
molecules) by the use of external energy to act as a driving force and/or reduce the barrier 
nature of the SC. The active methods cause stronger disruption of the SC barrier, while still 
protecting deeper tissues. The development of active methods was made possible by the 
emergence of technologies to localize effects to the SC combined with the safety issue 
(Brown et al., 2006). Table 3 shows various active methods of enhancing drug transport 
through the skin.   
Passive method Type 
Drug-vehicle interactions Drug/prodrug selection 
Ion pairs 
Eutectic systems 
Vesicles and particles Liposomes and analogues 
High velocity particles  
SC modification Hydration 
Chemical penetration enhancers 
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Table 3.  Active transdermal drug delivery strategies (Brown et al., 2006).  
Electroporation (EP) is currently one of the most promising modes of active 
enhancement for the noninvasive transdermal delivery of lipophilic, hydrophilic, charged or 
neutral molecules or macromolecules. EP involves the application of short (microsecond to 
millisecond) pulses of high voltage (100–1500 V) to achieve a transitory structural 
perturbation of the lipid bilayer membranes (Prausnitz et al., 1993; Neumann et al., 2000). Its 
main advantages are that it is an easy and rapid technique which is able to open the lipid 
bilayer membranes. Appropriate transdermal transport necessitates adjustment of the voltage, 
the pulse duration and the number of series of impulses (Wong, 2014). The appropriate skin 
EP for the transdermal transport of drugs with molecular weights up to 40 kDa across the skin 
can thereby be increased by several orders of magnitude (Lombry et al., 2000; Denet et al., 
2004).  
Currently the most rapidly developing area of EP is electrochemotherapy, which is an 
effective way of treating cutaneous and subcutaneous tumors. This method consists in 
applying high voltage pulses to permeabilize tumor cells to an impermeable cytotoxic drug 
which is given by injection either into a vein or directly into a tumor (Mir et al., 1999). 
2.3.3. Future prospects – combinations of enhancing methods 
Recent studies have suggested that suitably designed combinations of enhancing 
methods are safer and more effective than each of them alone (Prausnitz et al., 2008). The 
synergistic effects between EP and ultrasound, EP and iontophoresis or EP and 
pre/cotreatment with CPEs have been reported earlier (Vanbever et al., 1997; Zewert et al., 
1999; Mitragotri, 2000; Sen et al., 2002). However, not only the combination of two active 
  
Active method                                  Type 
  
Electrical methods Iontophoresis 
Electroporation 
Mechanical methods Microneedle/puncture/perforation 
Abrasion  
Needless injection 
Suction  
Stretching 
 
Miscellaneous  
 
Ultrasound 
Magnetophoresis  
Radio frequency 
Laser and photomechanical waves  
Temperature 
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methods or an active and a passive method can be successful. The high-throughput screening 
of 500 different pairs of CPEs was studied by Karande et al., who reported that a combination 
of appropriate CPEs could increase the skin permeability to macromolecules (~ 1–10 kDa) by 
up to ~ 100-fold without inducing skin irritation. For example, the potency and safety of a 
combination of sodium laureth sulfate and phenylpiperazine (a compound containing aromatic 
nitrogen) were confirmed by the transdermal delivery of leuprolide acetate (Karande et al., 
2004). Screening to find such synergistic combinations is continuing because it provides 
useful information for the development of a transdermal dosage form (Kling et al., 2007).  
3. EXPERIMENTAL AIMS 
The primary aim of my study was to investigate promising transdermal penetration 
enhancer techniques. To achieve this, the skin barrier structure was examined and different 
types of novel penetration enhancers were tested alone or in combination from the aspect of 
the achievement of the effective transdermal drug delivery. The following steps were set., 
1. In the first part of my Ph.D. work, the healthy and the diseased skin, especially the 
unaffected area in the psoriatic skin was studied in order to gain a deeper insight into the 
highly perturbed functions of the diseased SC, and to help to find the healthy volunteers 
for the skin measurements.   
2. In the second part, different penetration-enhancing strategies were optimized to ensure 
appropriate transdermal drug delivery. The aims were: 
o to compare the penetration-enhancing effect of a newly developed SE, sucrose 
myristate (SM), with the generally used sucrose laurate (SL); 
o to investigate the behavior of TR and SEs applied alone or in combination 
through the use of a Skin PAMPA artificial membrane system and human skin; 
o to examine the possibility of the spectral analysis of the effects of polyols in 
SLS-induced acute irritation; 
o to develop a suitable carrier for the poorly water-soluble, lipophilic 
phytocompound genistein (GEN); 
o to investigate the transdermal delivery of an LLC-based GEN-containing 
formulation (LLC-GEN) alone or in combination with EP; and  
o to test the recovery effect of LLC-GEN application and its combination with 
EP  on murine melanoma lesions.  
My Ph.D. work plan is summarized in Fig. 5. 
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Figure 5. Overall scheme of the Ph.D. work. 
4. MATERIALS AND METHODS 
4.1. Materials 
4.1.1. Sucrose esters and/or Transcutol-containing hydrogels 
A CPE-free hydrogel (Control gel) was prepared by the following procedure. 5 wt.% 
Ibuprofen (IBU, Sigma-Aldrich, St Louis, MO, USA) was dissolved in polyethylene glycol 
400 (20 wt.%) (Hungaropharma Ltd., Budapest, Hungary) and this solution was added to a 3 
wt.% Carbopol 971 (Lubrizol Corporation/Azelis, Budapest, Hungary) hydrogel prepared 
with distilled water. The pH was adjusted to 7.0 by adding trolamine (7 wt.%) 
(Hungaropharma Ltd., Budapest, Hungary).  
Two SEs, SL and SM, were purchased from Mitsubishi-Kagaku Foods Corporation, 
Tokyo, Japan. To compare the two SEs, 2.64 wt.% of each was incorporated individually in 
Carbopol 971-based hydrogel (SL gel and SM gel). 2.64 wt.% was chosen because this gave 
the maximum SE concentration-containing hydrogel which did not require a centrifugation 
process to remove the bubbles. Similar compositions were prepared by using 10 wt.% TR 
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(Gattefossé and Lubrizol Corporation/Azelis, Budapest, Hungary) (TR gel). 2.64 wt.% SE + 
10% TR-containing gels were prepared too (SL + TR and SM + TR gel). 
Different concentrations of SE-containing gels were also prepared by a similar method 
(SL 1; 2; 4; 6; 8; or 10 wt.% gel, SM 0.25; 0.5; 1; 2; 4; 6; or 10 wt.% gel) to investigate the in 
vitro diffusion influenced by the CPE contents. 
4.1.2. Genistein-containing lyotropic liquid crystal formulation 
GEN was purchased from Extrasynthèse (Genay, France; purity > 95%), and the 
nonionic surfactant Cremophor RH 40 (CRH40; Polyoxyl 40 Hydrogenated Castor Oil 
USP/NF) from BASF (Ludwigshafen, Germany). The aqueous phase of the systems was 
distilled water, and the oil phase was isopropyl myristate (IPM; Merck Kft., Budapest, 
Hungary).  
A GEN-free LLC was prepared by the following procedure. The oil–surfactant mixture 
(oil:surfactant ratio = 2:1) was homogenized with a magnetic stirrer at room temperature. 10 
wt.% of water was then added in small amounts to this mixture during stirring. A similar 
composition was prepared by using 3 wt.% GEN incorporated in the oil–surfactant mixture 
with a magnetic stirrer. 
4.2. Methods 
4.2.1. Drug diffusion and penetration investigations 
4.2.1.1. Franz diffusion cell method 
Membrane diffusion and permeability studies of active pharmaceutical ingredients 
(APIs) were carried out with a vertical Franz diffusion cell system (Hanson Microette TM 
Topical & Transdermal Diffusion Cell System, Hanson Research Co., Chatsworth, CA, USA).  
A stirring rate of 450 rpm was used. The receptor medium temperature was maintained at 37 ± 
0.5 °C throughout the experiments to support the physiological skin temperature (32 ± 0.5 °C) 
on the membrane in the Franz cell (Mura et al., 2009).
 
The donor phase was 0.30 g of sample, 
which was placed on a cellulose acetate membrane (Porafil, Machenerey-Nagel, Düren, 
Germany, and Pall Life Sciences, Washington, NY, USA) itself (in vitro), or in the case of ex 
ovo and ex vivo measurements the chorioallantoic membrane (CAM) and the epidermis were 
supported with the Porafil membrane filter. Samples of 0.8 ml were taken from the acceptor 
phase by the autosampler (Hanson Microette Autosampling System, Hanson Research Co., 
Chatsworth, CA, USA) and replaced with fresh receiving medium. Five parallel 
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measurements were made of the amount of drug that penetrated over a time period. The 
absorbance of the API content was measured with a Unicam Heλios α Thermospectronic UV-
spectrophotometer v4.55 (Unicam, Thermo Fisher Scientific, Waltham, MA, USA).  The 
further details of the investigations are summarized in Table 4.  
Table 4. Detailed parameters of drug diffusion and penetration investigations (BR: Britton-
Robinson buffer, PBS: phosphate buffer solution, SD: standard deviation, SEM: standard error 
of the mean). 
4.2.1.2. Skin PAMPA method 
The Skin PAMPA model involves recently published artificial membrane-based 
technology for the fast prediction of skin penetration. The method was reported previously 
(Vizserálek et al., 2015). 
4.2.1.3. Preparation of chorioallantoic membrane  
The CAM for the ex ovo experiment, was provided by Victor Babes University of 
Medicine and Pharmacy, Timisoara, Romania. The method of its preparation was described 
previously (Balázs et al., 2015). 
4.2.1.4. Preparation of heat-separated epidermis 
Excised human skin was obtained during abdominal plastic surgery on a Caucasian 
female patient. This was approved in advance by the Ethical Committee of the Human 
Investigation Review Board at Albert Szent-Györgyi Clinical Center, University of Szeged. 
The subcutaneous fat tissue was separated from the outer skin layers after the excision, and 
the skin was stored at −20 °C overnight. Then, after thorough defrosting, membrane 
separation was achieved with a previously reported method (Kligman et al., 1963). Individual 
portions were immersed in water at 60 °C for 90 s. After removal of the skin from the water, it 
Drug diffusion/penetration 
studies
in vitro ex vivo Skin PAMPA in vitro ex ovo ex vivo
API IBU IBU IBU GEN GEN GEN
Surface area 1.767 cm
2
1.767 cm
2 - 1.33 cm
2
1.33 cm
2
1.33 cm
2
Acceptor phase PBS (pH = 7.4) PBS (pH = 7.4) BR (pH = 7.4)
10 wt.% ethanol-
containing PBS (pH = 
7.4)
10 wt.% ethanol-
containing PBS (pH = 
7.4)
10 wt.% ethanol-
containing PBS (pH = 
7.4)
Time 24 h 16 h 16 h 24 h 24 h 48 h
Absorbance of the API 
content
263 nm 263 nm 263 nm 261 nm 261 nm 261 nm 
Results means ± SD means ± SD means ± SD means ± SEM means ± SEM means ± SEM
SEs and/or TR-containing hydrogels LLC-GEN
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was placed SC side up on a filter paper, and the epidermis (comprising the SC and the viable 
epidermis) was gently removed from the underlying dermis with the use of forceps. The latter 
was discarded and the epidermal membrane was floated onto the surface of PBS (pH = 7.4) 
for at least 20 min and then placed on a supporting Porafil membrane (cellulose acetate, pore 
diameter 0.45 μm) (Brain et al., 2007; Schroeder et al., 2007). 
4.2.1.5. Analysis of drug penetration 
In vitro IBU diffusion parameters were obtained from the cumulative amount of IBU 
diffused per cm
2
 (Q) versus time plots. The steady state flux (J) was obtained from the slope 
of the linear regression versus t
1/2
. The permeability coefficient (Kp) was calculated according 
to Fick’s first law of diffusion, based on J and the applied drug concentration (Cd) of the 
donor phase (Wagner et al., 2001):  
 Kp = J/Cd                                  (1) 
The effectiveness of CPEs was determined by comparing the Kp in the presence and 
absence of the CPE. This was defined as the enhancer index (EI), which was calculated by 
using the Kp of the hydrogel with the CPE (Kpe) and the Kp of the CPE-free Control gel (Kpef)  
(Vaddi et al., 2002):  
 EI = Kpe/ Kpef                                   (2) 
Ex vivo/Skin PAMPA penetration parameters of IBU were obtained from the cumulative 
amount of IBU penetrated per cm
2
 (Q) versus time plots. The J was calculated from the slope 
of the concentration versus time profile in the receiver compartment, and  expressed  in        
µg cm-2 h-1. For the linear regression analysis, the linear range of the incubation period from 1 
to 6 h was selected, and this range was used to calculate the flux data of the compounds. 
The effectiveness of the CPE was determined by comparing the flux of IBU in the 
presence and in the absence of the CPE. This was defined as the enhancement factor (EF), 
which was calculated via the following equation (Yan et al., 2007).
 
EF = (flux of the penetrant from the gel containing the CPE)/(flux of the penetrant from 
the   Control gel without the CPE)  
The flux data from the GEN investigations were obtained as described above in 
connection with the ex vivo/Skin PAMPA penetration parameters of IBU. 
Two-way ANOVA was performed to identify any significant difference in the diffused 
and penetrated amounts of IBU (Q) between the Control gel and the test preparations using 
(3) 
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GraphPad Prism software (Graph-Pad Software Inc., La Jolla, CA, USA). Differences were 
regarded as significant if p < 0.05*, p < 0.01* or p < 0.001***. 
 The correlation between the data on the Skin PAMPA model and the human epidermis 
was calculated via the following expression:                                                                                                             
   
           
                 
  
where R is the correlation,  x and y are the amounts of penetrated drug as a function of time in 
the case of the human epidermis and the Skin PAMPA model, respectively, and   and   are 
the average values of x and y. 
4.2.2. Skin hydration and transepidermal waterloss (TEWL) measurements  
Skin hydration was measured with a Corneometer
®
 CM 825 (Courage and Khazaka 
Electronic GmbH, Cologne, Germany). The TEWL measurements were performed with the 
Tewameter
®
 TM 300 instrument (Courage and Khazaka Electronic GmbH, Cologne, 
Germany). The TEWL is an indicator of the integrity of the skin barrier, and measurement of 
the TEWL is an easy and rapid noninvasive means of examining the effects of newly 
developed transdermal systems (Tanojo et al., 1998; Yilmaz et al., 2006). Measurements were 
performed under standardized conditions (room temperature of 21–23 °C, and 40–50% 
relative humidity). Seven healthy female volunteers aged between 23 and 60 years with no 
history of dermatological diseases or allergy participated in the experiment. Informed consent 
was obtained from all these volunteers and the study was approved by the local ethics 
committee (the Regional and Institutional Human Medical Biological Research Ethics 
Committee at the University of Szeged). The volunteers were asked not to apply any 
moisturizer or cosmetic product for at least 24 h before the process. They were given 30 min 
to adapt to the measurement room conditions. During the experiment, samples (0.30 g) were 
applied to the dorsal region of the hand (a 3 x 3 cm area) of all the subjects. The electrical 
capacitance of the SC, indicating the hydration level of the SC, was determined before and 30, 
90 and 150 min after the sample application. The measured values were compared with the 
values detected on the non-treated skin, and the changes in hydration were expressed as 
percentages. TEWL values were determined on the same area of the skin before and 30 and 
150 min after the sample application. The measured values were compared with the values 
detected on the non-treated skin, and the changes in TEWL were expressed as percentages 
(Nicander et al., 2004; Savic et al., 2004; Betz et al., 2005). Two-way ANOVA was 
(4) 
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performed to determine the statistical difference between the data for the various preparations 
and the Control gel; *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively 
(GraphPad Prism software). 
4.2.3. Polarization microscopic examinations 
The structures of the LLC samples were examined with a polarization microscope 
(LEICA Q500 MC Image Analyzer System) at room temperature. The magnification was 20x.  
4.2.4. Rheological investigations 
The rheological profiles of the samples were studied with a PaarPhysica MCR101 
rheometer (Anton Paar GmbH, Graz, Austria). The measuring device was of plate–plate type 
(diameter 25 mm, gap distance 0.2 mm). The measurements were carried out at 25 °C. The 
linear viscoelastic range was determined in the first step by examining the complex modulus 
as a function of the shear stress at a given frequency (1 Hz). On the basis of these 
experiments, the shear stress was set at 1 Pa during the dynamic testing as this value was 
always within the linear viscoelastic range. The storage and loss moduli values were 
examined as a function of frequency (0.01–10 Hz). 
4.2.5. Electroporation parameters 
The Mezoforte Duo EP device (Serial Number Mez 120905-D) produced by Dr Derm 
Equipment Ltd. (Budapest, Hungary) was provided by the Derm Clinic of Anti-Aging 
Dermatology, Aesthetic Laser and Plastic Surgery (Budapest, Hungary). The device operates 
on the basis of a pulsed electromagnetic field. The polypropylene-covered treating handpiece 
contains a 25 mm diameter plate electrode in direct contact with the treated surface. 
Modulation was achieved with high-voltage pulses with a voltage pulse duration of 5 ms, 
followed by a 20 ms break.  
4.2.6. Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy 
measurements 
ATR-FTIR spectroscopy is a suitable tool for studies of the structure of the SC at the 
molecular level, in order to characterize its lipids, proteins and water content (Dias et al., 
2008). The method allows analysis of the penetration of drugs into the skin and the 
biochemical modifications induced by the penetration (Csizmazia et al., 2012). ATR-FTIR 
combined with tape-stripping is essentially a nondestructive sampling technique which serves 
as a rapid, simple, noninvasive in vivo method for studies of the skin. Sequential tape-
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stripping permits the acquisition of SC layers from the deeper regions. The ATR device 
allows spectra to be taken from the surface of a sample without any preparation (Bommannan 
et al., 1990).  
ATR-FTIR spectra were recorded with an Avatar 330 FT-IR spectrometer (Thermo 
Nicolet, Waltham, MA, USA) equipped with a horizontal ATR crystal (ZnSe, 45°), between 
4000 and 400 cm
-1
, at an optical resolution of 4 cm
-1
. 128 scans or in the case of 
investigations of GLY and XYL, 64 scans were co-added and all spectral manipulations were 
performed with the Thermo Scientific's GRAMS/AI Suite software. No ATR correction was 
performed.  
For the investigation of human psoriatic skin, the components of the amide-I band and 
their relative intensities were estimated semiquantitatively in the 1695–1600 cm-1 region of 
the FTIR spectra by a curve-fitting algorithm, using Gaussian–Lorenzian mixing functions. 
The best fits were found by an iterative process minimizing the standard error. The results of 
curve-fitting were evaluated and analyzed statistically by Student’s t-test (Graph-Pad 
Software Inc., La Jolla, CA, USA). The data given are the averages of the results of 13 
parallel (3 psoriatic and 10 healthy) experiments ± SD (p < 0.05*, p < 0.01**). 
For animal experiments, in order to obtain a reference spectrum of the API, KBr pellets 
containing 0.5 mg of SLS or GEN were prepared and used. The spectra of treated and 
untreated samples were also recorded. Each average layer spectrum of the treated SC was 
corrected with the corresponding average layer spectrum of the untreated SC. To ensure that 
no absorbances from the skin itself remained and interfered with the results, the spectra of 
untreated control skin samples were subtracted from the spectra of water-treated control skin 
samples.  
4.2.6.1. Human experiments 
Psoriatic SC samples were obtained from 6 untreated psoriatic patients (3 males and 3 
females) aged between 32 and 64 years. Normal SC samples were collected from 20 healthy 
volunteers (10 males and 10 females) aged between 21 and 42 years with no history of 
dermatological disease. The study was approved by the local ethics committee (Government 
Office of Csongrád County Policy Administration Services of Public Health, PSO-SPEKT-
001). All volunteers were asked not to apply any moisturizer or cosmetic product for at least 
24 h before the process. The forearm skin of each volunteer was stripped with adhesive 
cellophane tape; this was repeated up to 25 strips. In the case of the psoriatic patients, the 
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samples were taken from the unharmed skin of the forearm. Every first tape with one strip 
was discarded because of the possibility of surface contamination. Every second adhesive tape 
with three strips was analyzed, because this gave the most intensive IR spectrum.  
4.2.6.2. Animal experiments 
12–15 week old male SKH-1 hairless mice were housed in plastic cages in a 
thermoneutral environment with a 12 h light-dark cycle and had access to standard laboratory 
chow and water ad libitum. All interventions were in full accordance with the NIH guidelines 
and the protocols were approved in advance by the Ethical Committee for the Protection of 
Animals in Scientific Research at the University of Szeged (licence number: V./145/2013).  
4.2.6.2.1. Spectroscopic investigations of the effects of polyols in sodium lauryl 
sulfate-induced acute irritation  
Mice were randomly allocated into six groups. Group 1 (n = 23) served as a control 
treated with purified water. Group 2 (n = 23) was exposed to a 5 wt.% solution of SLS. In 
group 3 (n = 23), the solution applied to the skin contained 5 wt.% SLS and 5 wt.% GLY. The 
animals in group 4 (n = 23) received a solution containing 5 wt.% SLS and 8.26 wt.% XYL. 
Group 5 (n = 23) was treated with 5 wt.% SLS and 10 wt.% GLY, while in group 6 (n = 23), 5 
wt.% SLS and 16.52 wt.% XYL were applied to the skin. The SLS and the polyols were 
dissolved in purified water. The appropriate GLY and XYL solutions were equiosmolar. In 
each group, 15 mice were randomly chosen for patch testing. In closed patch tests, extra-large 
Finn Chambers (diameter 18 mm) and corresponding filter discs soaked with 120 μl of the test 
solutions were applied to the dorsal region for 3 h, using Scanpore tape (SmartPractice, 
Phoenix, AZ, USA). The relative humidity was 40–50% and the ambient temperature was 
kept at 20–22 °C. The patch testing was followed by ATR-FTIR. The corneocytes were 
obtained from the dorsal region of the patch-tested mice with adhesive cellophane tape. This 
was repeated up to 25 strips, an IR spectrum being recorded after each third tape strip. Every 
first tape with one strip was discarded because of the possibility of surface contamination. The 
untreated dorsal skin of the mice was stripped and measured with the same method. Data 
analysis was performed with SigmaStat (Systat Software Inc., Chicago, IL, USA). Differences 
between groups were analyzed with Kruskal-Wallis one-way analysis of variance on ranks, 
followed by the Dunn method for pairwise multiple comparison. p < 0.05* was considered 
statistically significant. 
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4.2.6.2.2. Investigations of Genistein-containing lyotropic liquid crystal  
The mice involved in this study were divided into 5 groups as follows:  
Group I: mice treated with dermally applied LLC-GEN for 2 min (conventional 
treatment) 
Group II: mice treated with LLC-GEN and EP at 700 V for 1 min  
Group III: mice treated with LLC-GEN and EP at 900 V for 1 min 
Group IV: mice treated with LLC-GEN and EP at 700 V for 2 min  
Group V: mice treated with LLC-GEN and EP at 900 V for 2 min 
5 mice were randomly assigned to each experimental condition. Corneocytes were 
collected from the uppermost layer of their dorsal skin with the use of adhesive tape (D 
Squames, CuDerm Corporation, Dallas, TX, USA) immediately after treatment. The treated 
and the untreated dorsal skin of each mouse was stripped with adhesive tape; this procedure 
was repeated up to 18 strips, an IR spectrum being recorded after every third tape strip. Every 
first tape with one strip was discarded because of the possibility of surface contamination. 
Two-way ANOVA was used to identify any significant differences in the total penetrated 
amount of GEN between the conventional treatment and the combined EP treatments by using 
GraphPad Prism software. Differences were regarded as significant if p < 0.05*.  
4.2.7. Raman measurements 
For Raman measurements, 2 mice were randomly assigned to each of groups I, III and 
V as described in section 4.2.6.2.2. “Investigations of Genistein-containing lyotropic liquid 
crystal”. At the end of the observation period, the animals in these groups were sacrificed and 
full-thickness skin samples were excised from the treated areas. The samples were embedded 
in Cryomatrix resin (Thermo Fisher Scientific Inc., Waltham, MA, USA) and cryosections of 
6 μm were made.       
Raman spectra were acquired with a Dispersive Raman Microscope (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) equipped with a CCD camera and a diode laser 
operating at 780 nm. The spectra of CRH40, IPM and GEN were collected with an exposure 
time of 6 s, with 48 scanning and cosmic ray and fluorescence corrections. Raman 
measurements were carried out with a laser power of 12 mW at a slit width of 25 µm. The 
localization of GEN in the skin samples was investigated by confocal Raman mapping. For 
mapping, the microtomed skin samples as depth sections were rotated by 90° and placed on 
an aluminum surface with the SC toward the top of the plate. Thus, a 1000 µm length of the 
sample specimen corresponds to a 1000 µm depth into the skin. The mapping was achieved in 
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a point-by-point mode, using a step size of 10 µm perpendicular and parallel to the SC. 
Raman maps of skin with dimensions 30–40 µm parallel and 900–1300 µm perpendicular to 
the SC surface were generated one by one. The spectrum acquisition time was 3 s per 
spectrum, and 24 spectra were accumulated and averaged at each measured point, these 
parameters ensuring an acceptable signal-to-noise ratio. The mapping was carried out with a 
laser power of 24 mW at a slit width of 25 µm. The vibrational chemical images were studied 
by a multivariate curve resolution – alternating least squares (MCR-ALS) chemometric 
method; the purpose was to identify GEN in the Raman spectra. 
4.2.8. Murine melanoma investigations  
Animal studies were conducted on 7–8 week old C57BL/6J female mice with an 
average weight of 20–25 g, purchased from Charles River (Sulzfeld, Germany). The 
experiments were conducted in accordance with the rules of the Ethical Committee of Victor 
Babes University of Medicine and Pharmacy, Timisoara, Romania. The number of mice 
involved in the study was 30, divided equally into 6 groups of 5 animals as follows:  
Group A: blank group 
Group B: mice inoculated with B164A5 cells and otherwise not treated 
Group C: mice inoculated with B164A5 cells and treated with LLCs without GEN 
Group D: mice inoculated with B164A5 cells and treated with LLCs with 3 wt.% GEN 
Group E: mice inoculated with B164A5 cells and treated with LLCs without GEN and 
EP at 900 V for 6 min  
 Group F: mice inoculated with B164A5 cells and treated with LLCs with 3 wt.% 
GEN and EP at 900 V for 6 min  
On day 0 of the experiment, the mice in groups B–F received a subcutaneous (s.c.) 
inoculation of 0.1 ml containing 1*10
6
 cells/mouse into the depilated lateral abdomen. For the 
mice in groups C–F, treatment with 2 ml of a 3 wt.% LLC-GEN formulation was 
administered from day 2 post-inoculation, using 6 min of high voltage EP or the classical 
application as described above. The mice were inspected daily for the development of tumors 
or other changes. Results are presented as means ± SD. One-way ANOVA followed by the 
Bonferroni test was used to determine the statistical difference between the various 
experimental and control groups; *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001. 
Tumor growth was measured daily in millimeters, using calipers, and the tumor volume was 
estimated by the formula: length x width
2
/2. The mice were subsequently sacrificed by 
cervical dislocation.   
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5. RESULTS AND DISCUSSION 
5.1. Investigation of the unaffected skin area in the psoriatic skin 
One of the most common applications of FTIR spectroscopy in protein studies is the 
analysis of secondary structure. FTIR spectroscopy involves the measurement of the 
wavelength and intensity of the absorption of IR radiation by a sample. The amide-I band 
region (1700−1600 cm-1) is the spectral region most sensitive to the secondary structural 
components of the proteins; this is due very largely (approximately 80%) to the C=O stretch 
vibrations of the peptide linkages.  Fourier self-deconvolution (FSD), a band-narrowing 
method, has not only enriched the qualitative interpretation of IR spectra, but has also 
provided a basis for the semiquantitative estimation of the secondary structure of proteins 
(Kong et al., 2007; Hadgraft et al., 2011). 
The amide-I band appears clearly in the ATR-FTIR spectrum of the skin in consequence 
of the coupling of the transition dipole moments of the amide groups within the protein 
backbone. Various protein secondary structures have their own characteristic amide-I bands. 
However, because of the strong overlap between the characteristic bands, the amide-I bands 
of the recorded IR spectra are too complex to permit the direct determination of the 
components with various secondary structures (Barth, 2007).  
Band-narrowing procedures such as FSD and curve-fitting greatly enhance the potential 
of this band as a meaningful structural probe. Such mathematical processes increase the 
degree of separation by narrowing the half-bandwidths of the individual components for 
easier visualization without seriously distorting the spectrum. The main disadvantage of this 
procedure is its tendency to magnify both the signal and the noise in the spectrum. This causes 
a dramatic increase in the noise level, which necessitates coupling the FSD with a smoothing 
function (Lamba et al., 1993; Al-Mustafa, 2002; Kong et al., 2007). 
FSD of the corresponding ranges of the recorded spectra was used to determine the 
approximate frequencies of the components of the amide-I bands indicating the presence of 
protein chain sections with various secondary structures (Pelton et al., 2000; Barth, 2007). 
Seven bands were fitted to all the spectra and their areas were compared (Fig. 6). The ratios of 
the integrated band areas provide an estimate of the proportions of the parts with various 
secondary protein structures.  
A protein molecule is formed from a chain of amino acids. The secondary structure of a 
protein is determined by the set of dihedral angles (φ and ψ) which define the spatial 
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orientation of the peptide backbone, and the presence of specific hydrogen-bonds. Regular 
secondary structures include α-helices and β-sheets. An ideal α-helix has 3.6 residues per turn, 
and is built up from a contiguous amino acid segment via backbone−backbone hydrogen-bond 
formation between amino acids in positions i and i + 4. The residues taking part in an α-helix 
have φ angles around −60° and ψ angles around −45°.  
 
Figure 6. The original FTIR spectra of the SC and the deconvolved and curve-fitted 
components. 
β-sheets are created when atoms of β-strands are hydrogen-bonded. β-sheets may 
consist of parallel strands, antiparallel strands or a mixture of parallel and antiparallel strands. 
In parallel β-sheets the strands run in one direction, whereas in antiparallel sheets they run in 
alternating directions. The dihedral angles of the β-sheet are φ ~ −130° and ψ ~ −120°, 
forming an extended structure with some right-handed twist.  
Turns allow a protein to fold back on itself and are stabilized by a hydrogen-bond that 
holds the ends together. They are classified according to the number of residues involved in 
the hydrogen-bonded structure. Unordered structure is generally defined as a conformation 
that is not helix, sheet or turn (Pelton et al., 2000). 
In the SC, greater flexibility is achieved through loose packing of the keratin filaments 
and a lower number of disulfide crosslinks. It was observed that the overall intensities of the 
amide-I bands were lower for the psoriatic SC than for the healthy SC (Fig. 7), but the peak at 
1660 cm
-1
 exhibited the most pronounced alteration, as shown in Fig. 8.  
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Figure 7. Differences in intensity between a normal SC and a psoriatic SC spectrum: (a) man; 
(b) woman. 
Figure 8. Areas of the fitted components of the amide-I band in the cases of normal and 
psoriatic SC: (a) man; (b) woman. 
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The proteins in the SC are mainly in α-helical conformation (Gniadecka et al., 1998). 
The peak at 1650 cm
-1
 indicates the presence  of an α-helix (Fig. 8), which  always has the  
largest area. We focused on the peak at 1660 cm
-1
, characteristic of the turns in the protein 
chain (Pelton et al., 2000). It was observed that the overall intensities of the amide-I bands 
were lower for the psoriatic SC than for the healthy SC, but the peak at 1660 cm
-1
 exhibited 
the most pronounced alteration, as shown in Fig. 8. The intensity of this peak decreases 
almost to zero in psoriatic patients, indicating the drop in concentration in the turn protein 
regions (Table 5). The results for men and women are given separately, because of the 
differences in skin between the genders (Tur, 1997). 
Table 5. Decreased integrated area of amide-I protein structures in psoriatic skin. 
Conformation β-sheet α-helix Turns β-sheet Turn 
Wavenumber [cm
-1
] 1620 1640 1650 1670 1680 1630 1660 
Healthy men mean 
integrated area (±SD) 
0,28 
(0,11) 
0,96 
(0,24) 
1,85 
(0,58) 
0,62 
(0,15) 
0,18 
(0,14) 
0,32 
(0,25) 
0,36 
(0,17) 
Psoriatic men mean 
integrated area (±SD) 
0,07 
(0,04) 
0,28 
(0,24) 
0,54 
(0,30) 
0,16 
(0,12) 
0,05 
(0,02) 
0,04 
(0,005) 
0,03 
(0,03) 
Integrated area 
percentage (%) of 
psoriatic over healthy 
24,6 29,4 29,3 25,9 29,3 13,2 9,2 
Healthy women mean 
integrated area (±SD) 
0,12 
(0,10) 
0,62 
(0,14) 
1,27 
(0,52) 
0,34 
(0,16) 
0,14 
(0,03) 
0,20 
(0,10)  
0,23 
(0,06) 
Psoriatic women 
mean integrated area 
(±SD) 
0,07 
(0,02) 
0,29 
(0,01) 
0,55 
(0,19) 
0,23 
(0,06) 
0,05 
(0,03) 
0,08 
(0,04) 
0,02 
(0,01) 
Integrated area 
percentage (%) of 
psoriatic over healthy 
64,4 47,4 43,1 67 33,9 3,9 9,7 
Fig. 9 compares the areas of the peak at 1660 cm
-1
 for the healthy control group and the 
psoriatic patients. As a result of the presence of psoriasis, the intensity of this band is 
significantly lower for both males (p < 0.05*) and females (p < 0.01**). The areas of all the 
amide-I band components are less in the psoriatic group, but the decrease is especially marked 
in the cases of the bands at 1630 and at 1660 cm
-1
 (Fig. 8). The former is in the middle of the 
region characteristic of the β-sheet structure, and the latter reflects the turn structure. The fall 
in the intensity of the latter suggests the loss of those parts of the protein structure even in the 
unharmed psoriatic SC which provide the protein with flexibility. 
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Figure 9. Percentage contributions of the components of the amide-I band for psoriatic and 
healthy patients of both genders. 
5.2. Examination of transdermal penetration enhancers 
5.2.1. Study of Sucrose esters and/or Transcutol-containing hydrogels  
5.2.1.1. Drug diffusion and penetration measurements 
The in vitro and in vivo skin permeability of IBU is improved by the use of a 
hydrophilic vehicle alone (Lee et al., 1993), but it is increased even more by the application of 
CPEs such as SEs (Csizmazia et al., 2012). First, in order to investigate how the SEs 
influenced the diffusion of IBU in vitro, we tested the 2.64 wt.% SE content formulations.  
Fig. 10 presents the cumulative amount per unit area of IBU diffused through the synthetic 
membrane from the different formulations against time. Without CPEs, the drug liberation 
was about 6687.58±823.86 µg cm-2 in 24 h. Both 2.64 wt.% SE-containing hydrogels 
increased IBU diffusion, but in this concentration great differences were not observed 
between the different SEs. Although the SL-containing hydrogel caused a slightly slower drug 
release than the Control gel in the first few hours, the cumulative drug amount in 24 h was 
greater than that in the case of the Control gel. The diffused drug amounts were not 
statistically significant in this case. However, when SM was used, the amount of the liberated 
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drug was similar to that in the case of the Control gel in the first 3 h, but after 9 h the 
difference between the amounts of IBU diffused from the Control gel and the SM gel was 
statistically significant (p < 0.05*).   
Figure 10. The cumulative diffused amount of IBU through synthetic membrane. 
Next, to examine the effects of the CPE concentrations on the in vitro drug diffusion, 
we carried out in vitro tests with both SE gels in different concentrations. The in vitro fluxes 
(representing the absorption rate per unit area) and the EIs suggest that SL has a 
concentration-dependent enhancing effect (Table 6). It can be seen that from 2 wt.% SL 
content the EI values and the amount of IBU diffused after 24 h were better than in the case of 
the CPE-free hydrogel. We observed a maximum curve and the best penetration of IBU was 
strengthened by the 6 wt.% SL gel (Fig. 11). This gel showed the highest IBU diffusion 
profile and after 10 h the results were significant. The 8 wt.% and 10 wt.% SL-containing 
hydrogels resulted in lower penetration parameters than those with the 6 wt.% SL gel.  
The studies with SM revealed the same tendency. A maximum curve was again 
observed, but this curve reached the maximum at much lower SE concentration, 0.5 wt.%. 
The diffusion profile of IBU from the 0.5 wt.% SM-containing gel revealed the highest drug 
release and after 3 h this formulation showed the earliest significantly increased diffused IBU 
amount (p < 0.05*)  relative to the Control gel (Fig. 11). This gel gave the best IBU diffusion 
profile and enhanced the IBU diffusion 1.5-fold as compared with the EI value of the 6 wt.% 
SL gel. The EIs further demonstrated that SM up to 4 wt.% is more effective than SL for 
enhancing the diffusion of IBU through a synthetic membrane (Table 7).  
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Table 6. Parameters of IBU diffusion from different SL-containing hydrogels after 24 h. 
Table 7. Parameters of IBU diffusion from different SM-containing hydrogels after 24 h. 
Figure 11. The amount of IBU diffused from different SL and SM-containing hydrogels 
after 24 h. 
Table 8 presents the parameters of IBU penetration through excised human epidermis. 
The SE gels increased the penetration of IBU through the skin appreciably as compared with 
the CPE-free Control gel, but the TR gel did not enhance the IBU penetration. TR is thought 
to give rise to its penetration-enhancing function by increasing the solubility of the applied 
drug. However, TR has also been observed to display an accumulation property by increasing 
Formulation Q (μg cm
-2
) J (μg cm
-2
 h
-1
) Kp · 10
-3 
(cm h
-1
) Enhancer Index (EI)
Control gel 6687.59 ± 869.12 971.73 19.43 1.00
SL 1% gel 2443.09 ± 425.22 117.05 2.34 0.12
SL 2% gel 7002.61 ± 1674.47 1248.60 24.97 1.28
SL 2.64% gel 8213.55 ± 1092.08 1629.60 32.59 1.68
SL 4% gel 8331.24 ± 478.75 1619.40 32.39 1.67
SL 6% gel 10824.16 ± 1130.68 2282.30 45.65 2.35
SL 8% gel 10317.58 ± 1736.76 2233.70 44.67 2.29
SL 10% gel 7542.37 ± 930.57 1575.60 31.51 1.62
Formulation Q (μg cm
-2
) J (μg cm
-2
 h
-1
) Kp · 10
-3 
(cm h
-1
) Enhancer Index (EI)
Control gel 6687.59 ± 869.12 971.73 19.43 1.00
SM 0.25% gel 11075.59 ± 1251.89 2166.20 43.32 2.76
SM 0.5% gel 14166.39 ± 549.12 2792.30 55.85 3.56
SM 1% gel 11753.84 ± 1152.88 2192.80 43.86 2.79
SM 2% gel 10449.58 ± 766.22 2109.20 42.18 2.69
SM 2.64% gel 9999.87 ± 1581.83 1932.80 38.66 2.46
SM 4% gel 9675.14 ± 1784.70 1927.90 38.56 2.46
SM 6% gel 7198.69 ± 1070.05 1387.00 27.74 1.77
SM 10% gel 1619.33 ± 282.15 312.24 6.24 0.39
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the skin accumulation of topically applied drugs without a concomitant increase in 
transdermal penetration. TR causes the swelling of intercellular SC lipids, and lipophilic 
drugs such as IBU are trapped within the swollen SC lipids (Godwin et al., 2002). 
Table 8. Parameters of IBU penetration through the human epidermis after 16 h. 
Formulation Q (μg cm-2) J (μg cm-2 h-1) EF 
Control gel 463.95±110.50 42.72 - 
TR gel 193.36±87.13 14.23 0.33 
SL gel 866.79±320.42 67.93 1.59 
SM gel 889.22±348.09 54.28 1.27 
SL + TR gel 825.08±384.67 54.38 1.27 
SM + TR gel 1527.19±764.62 91.59 2.14 
As regards SEs, SL (C = 12, HLB = 16) and SM (C = 14, HLB = 16) were selected 
because SEs with lower C numbers and higher HLB values increase the drug release more 
than do SEs with longer fatty acids and lower HLBs (Csóka et al., 2007). SL has been 
reported to maximize the effect of a surfactant on membrane permeability (Park et al., 2000).
SEs may act by disrupting the ceramide–cholesterol or cholesterol–cholesterol interaction. 
Increase of the carbon chain length of the fatty acids results in their molecular weights 
increasing, and their mobility within the skin layers is expected to decrease, which may 
explain their lower penetration enhancement effect (El-Laithy et al., 2009). Ex vivo fluxes 
reveal that SL induces faster IBU release than does SM, whereas the amount of penetrated 
IBU after 16 h was higher in the case of the SM gel. The ex vivo drug release behavior data 
indicated that SL was not a better penetration enhancer for IBU than SM (Table 8).  
In contrast with the application of TR alone, it has been reported that its combination 
with SE resulted in facilitated surfactant absorption into the deeper layers of the SC. This 
synergistic enhancement between SE and TR affects only the penetration depth of the 
formulation and does not increase the amount of drug that penetrates (Ayala-Bravo et al., 
2003). The SM + TR gel exhibited the best penetration parameters (Table 8). The SL + TR 
gel resulted in a lower penetration than that with the SL gel, but the difference was not 
statistically significant.  A possible reason for this phenomenon could be that the TR depot 
effect predominated in the case of the SL + TR gel, because SL is not able to cause so much 
lipid disruption. In contrast with SL, SM may cause a greater extent of lipid alteration through 
its higher carbon chain and this prevents the TR depot effect. Furthermore, SM in 
combination with TR proved to penetrate the skin well, and there was a marked increase in 
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IBU release from the SM + TR gel as compared with the Control gel. The ex vivo statistical 
analysis indicated that only the SM + TR gel resulted in a significantly (p < 0.001***) higher 
penetrated IBU amount relative to the Control gel after 7 h. 
Table 9 presents the penetration data on the different transdermal formulations tested 
with the Skin PAMPA system. Lower standard deviation and higher penetration data are 
observed with the PAMPA model than with the Franz cell method, which may be caused by 
the differences in the membrane structure in the two procedures. However, the penetration 
profiles obtained with the Skin PAMPA and ex vivo Franz cell methods were in good 
agreement in most cases (Fig. 12).  
Table 9. Parameters of IBU penetration through the Skin PAMPA model after 16 h. 
Formulation Q (μg cm-2) J (μg cm-2 h-1) EF 
Control gel 5204.95±311.23 432.35 - 
TR gel 4941.95±966.97 329.95 0.76 
SL gel 5642.38±383.43 517.06 1.20 
SM gel 5812.12±150.72 512.81 1.19 
SL + TR gel 5616.67±208.33 483.72 1.12 
SM + TR gel 6062.98±121.23 563.1 1.30 
Figure 12. The correlations between the amounts of IBU penetrated through human skin and 
Skin PAMPA. 
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The differences between the PAMPA and Franz cell results clearly indicate the TR 
depot phenomena which can not be observed through the synthetic membrane (Park et al., 
2000).
 
The decreased amount of IBU that penetrated from the TR gel relative to the Control 
gel was statistically significant after 3 h (p < 0.001***). The penetration-enhancing effect of 
the SEs is clear. Whereas SL rather hampers the penetration through the synthetic membrane, 
it increases the penetration of IBU efficiently through the Skin PAMPA or the human 
epidermis (Park et al., 2000). The SM gel caused only a slightly lower flux than that with the 
SL gel, yielding a significantly higher penetration profile as compared with the Control gel 
after 4 h (p < 0.01**) and as compared with the SL gel after 7 h (p < 0.001***). The 
combination SL + TR also demonstrated a lower penetration profile, as can be seen in the 
case of the ex vivo result. The penetration profile of IBU from the SM + TR gel showed the 
earliest significantly increased diffused IBU amount (p < 0.001**) after 3 h as compared with 
the Control gel, and after 7 h as compared with the SM gel. The highest average penetration 
profile of IBU was seen with this gel. This result was verified by both the Skin PAMPA and 
the Franz cell method.  
The determination coefficients (R
2
) of linear regression of the correlation between the
amount of IBU that penetrated through the human skin and the amount of IBU that penetrated 
through the Skin PAMPA indicated a good correlation. The determination coefficients 
between the in vitro PAMPA and the ex vivo Franz cell methods were in the range 0.88–0.99 
(Fig. 12). The EF values observed with the ex vivo and in vitro methods were of the same 
order of magnitude in all five cases (Fig. 13). 
Figure 13. Ex vivo (human epidermis) and in vitro (Skin PAMPA) enhancement factors 
of different formulations. 
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5.2.1.2. In vivo skin tests 
The penetration of a drug into the deeper layers can be enhanced through a well-
hydrated skin, too. During moisturizing, the intercellular space between the corneocytes 
increases due to the swelling of the SC. Fig. 14 shows that every investigated sample 
increased the hydrated state of the skin and ensured a good, lasting moisturizing effect. The 
greatest increase in skin water content were obtained with the 2.64 wt.% SM gel and the SM + 
TR gel. The application of the 2.64 wt.% SM gel or SM + TR gel results in significantly 
higher skin hydration relative to the Control gel after 30, 90 and 150 min (p < 0.001***). The 
Control gel and the 2.64 wt.% SL gel showed a similar hydration state after 30 min, but after 
90 min the 2.64 wt.% SL gel achieved a greater and more enduring moisturizing effect than 
that with the Control gel. However, the results were not statistically significant as compared 
with the SE free hydrogel (Fig. 14a).  
Figure 14. Skin water hydration (a) and TEWL measurement after (b) 30 min and (c) 
150 min treatment with the single application of six IBU-free topical formulations. 
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It was proved earlier that SL acts as an effective and non-irritating hydration and 
penetration enhancer for IBU through the skin (Csizmazia et al., 2011). From our results, it 
can be concluded that the SEs incorporated into the hydrogel vehicle interact synergistically 
to modify the skin barrier, but statistically SM achieved a higher skin water-holding capacity 
increase. The SEs have the same HLB value (HLB = 16), but with the 14 C-atom-long fatty 
acid chains, SM in a hydrogel formulation is probably able to integrate into the SC lipid 
bilayer more efficiently than SL (C = 12).  
TEWL measurement is the most appropriate noninvasive model with which to study the 
skin barrier function and its change effected in the dermal preparation. Application of the 
control formulation leads to lower TEWL values than the level before treatment. Even after 
150 min, the skin was well protected and lastingly by the Control gel. This phenomenon can 
be seen in the cases of TR, SM and the combination SM + TR. Treatment with SL or SL + 
TR-containing gels resulted in only slight increases in TEWL. The changes were not 
statistically significant as compared with the Control gel. The skin barrier structure remained 
basically unaltered for all the tested formulations. Although TR and the SEs caused minimal 
modifications in the SC barrier structure (Cázares-Delgadillo et al., 2005; Csizmazia et al., 
2011), these hydrogel-based trandsdermal preparations protected the special SC structure 
(Fig. 14b, c).  
5.2.2. Spectroscopic investigations of the effects of polyols in sodium lauryl sulfate-
induced acute irritation  
The penetration of the dermal preparation components emerge as viewpoint from 
pharmaceutical technology development of dermal formulations. The penetration 
characteristics of SLS, as frequently used components, in the presence of the polyols were 
therefore studied with combined tape stripping and ATR-FTIR spectroscopy (Dias et al., 
2008; Balázs et al., 2014). ATR-FTIR spectroscopy revealed the most characteristic bond of 
SLS assigned to the SO2 stretch (asymmetric) at 1220 cm
-1
 (Fig. 15) (Bhise et al., 2009). It 
was found that both lower concentration polyol treatments modified the SLS penetration, but 
a significant decrease in the amount of SLS in the deeper layers was observed when higher 
polyol treatments were applied (Table 10). 
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Figure 15. ATR-FTIR spectra of pure SLS, a 5 wt.% solution of SLS and the non-
treated SC. 
Table 10. Intensities in the upper and lower layers of the treated SC (relative 
absorbance of SLS at 1220 cm
-1
). Median values (M) with 25
th
 and 75
th
 percentiles. 
 Group 2 
(SLS 5 %) 
Group 3 
(SLS + GLY 5 %) 
Group 4 
(SLS + XYL 8.26 %) 
Group 5 
(SLS + GLY 10 %) 
Group 6 
(SLS + XYL 16.52 %) 
Number 
of layers 
M 25p; 
75p 
M 25p; 
75p 
M 25p; 
75p 
M 25p; 
75p 
M 25p; 
75p 
1-
4 
0.0226 0.0137
; 
0.0309 0.0187; 0.0318 0.0181; 0.0319 0.0161; 0.0196 0.0134; 
0.0264 0.0518 0.0468 0.0532 0.0360 
5-
8 
0.0234 0.0140
; 
0.0223 0.0122; 0.0241 0.0149; 0.00601 0.00143; 0.000 0.000; 
0.0433 0.0300 0.0454 * 0.0134 * 0.0133 
GLY may reduce the average aqueous pore radius in the SC, thereby decreasing the 
penetration of irritants (Ghosh et al., 2007), it may be presumed that the anti-irritant and anti-
inflammatory effects of GLY and XYL are just elucidated by the hampered penetration of 
SLS. The penetration of SLS to the deeper SC layers decreased significantly at higher polyol 
concentrations, which is a novel feature for XYL. However, this result is not completely in 
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accordance with the previous observed effects of polyols, where XYL merely proved to be 
effective at lower concentration. In addition, the hydrating effects of polyols are independent 
of their action on SLS penetration.  
5.2.3. Investigations of Genistein-containing lyotropic liquid crystal  
5.2.3.1. Polarization microscopic examinations 
In the development of the dermal delivery, we prepared an LLC formulation which is 
capable of suspending and partly dissolving GEN in a concentration of 3 wt.%. Fig. 16 
presents a polarization microscopic picture of the developed LLC structure, revealing a 
lamellar LLC pattern with a characteristic ribbon structure in polarized light.  
Figure 16. Polarizing microscopic examination of blank LLC at a magnification 
of 20x. 
5.2.3.2. Rheological investigations 
The characteristics of the LLC system include the frequency-dependent storage and loss 
moduli. In the investigated frequency range, the blank LLC system is more elastic than 
viscous. The solubilization of GEN in the LLC system led to a consistency increase (Fig. 17). 
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Figure 17. Rheological characterization of the blank and GEN-containing LLC formulations. 
5.2.3.3. Drug diffusion and penetration measurements 
The membrane diffusion investigations indicated that good drug release and diffusion 
was attained through the synthetic membrane in vitro, 713.26±90.73 µg cm-2 being liberated 
in 24 h (Fig. 18a). Somewhat less drug was observed after 24 h (491.26±15.55 µg cm-2) in the 
case of ex ovo penetration (Fig. 18b). In the ex vivo investigations which revealed not only the 
amount of drug that diffused through the skin, but also the interaction with the skin and the 
incidental reservoir function of the SC, only a small amount of drug penetrated through the 
human epidermis (8.93±1.81 µg cm-2 after 24 h and 15.68±3.09 µg cm-2 after 48 h), but the 
penetration profile was similar to that for ex ovo penetration and sustained drug release was 
achieved (Fig. 18c). The J values showed that the drug penetration was slowed down by the 
application of the biological membrane, and that LLC-GEN alone was not sufficient to reach 
an appropriate plasma concentration.   
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Figure 18. Amount of GEN diffused in vitro (a), or penetrated ex ovo (b) or ex vivo 
(c). 
5.2.3.4. ATR-FTIR spectroscopy  
The results showed that the traditionally used LLC-GEN was not effective alone. The 
LLC-GEN formulation was therefore combined with an active penetration-enhancing method, 
EP. Different treatment times and voltages were used. The penetration profile of GEN within 
the different layers of the SC was established with a combination of tape stripping and ATR-
FTIR spectroscopy. The most characteristic peaks in the ATR-FTIR spectrum of GEN were 
assigned to the C1=C2 stretch at 1652 cm
-1
,
 
and the C=O stretch, O7-H22 bend, and ring A C-
C stretch at 1518 cm
-1
 (Fig. 19) (Surendra Babu et al., 2012).  
Table 11 presents the relative absorbances in the SC layers at 1652 cm
-1 
and 1518  cm
-1
, 
which correspond to the amounts of GEN that penetrated into the SC after conventional and 
EP treatments (Fig. 20). The drug delivery and the onset time for transport depend on the 
electrical parameters of the pulses and the physicochemical properties of the drug (Denet et 
al., 2004). It was found that EP treatment at 700 V for 1 min did not enhance the GEN 
transdermal delivery relative to the conventional treatment. This may be explained by the high 
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viscosity of the drug carrier, which decreases the efficacy of EP on the skin (Vanbever et al., 
1995). Slightly deeper GEN penetration was ensured by EP treatment at 900 V for 1 min, but 
the total amount of GEN did not exceed that for conventional treatment with LLC-GEN. 
However, EP treatment at 700 V for 2 min resulted in a deeper penetration of a 2-fold amount 
of the drug than without EP treatment (revealed at both characteristic bonds of GEN). The 
best penetration profile of GEN was obtained on EP treatment at 900 V for 2 min, when the 
total amount of the drug was 3-fold greater as compared with conventional treatment at both 
assigned bonds (p < 0.001*** and p < 0.05*), but the GEN distribution was not consistent. 
The presence of GEN was not seen in the 5
th
 and 6
th
 tape strips, whereas the drug appeared 
again in the 7
th
 strips. This phenomenon could be explained by the electrical breakdown of the 
SC layers. Furthermore, the amount of drug that penetrated increased with increasing voltage 
of the pulses (Prausnitz et al., 1993; Vanbever et al., 1996).  
Figure 19. ATR-FTIR spectra of pure GEN (a), CRH40 (b), IPM (c), LLC-GEN composition 
(d) and non-treated SC (e). 
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Table 11. Intensities of GEN in the different layers of the treated SC (average value ± SD, n = 
3) (CT = conventional treatment). 
 
Figure 20. Total intensities of GEN at 1652 cm
-1
 and at 1518 cm
-1
. CT was used as a control. 
p < 0.001*** and p < 0.05* vs. EP-treated group. 
 
 
Treated with LLC-
GEN (CT, 2 min) 
Treated with LLC-
GEN + EP (700 V, 1 
min) 
Treated with LLC-
GEN + EP (900 V, 1 
min) 
Treated with LLC-
GEN + EP (700 V, 2 
min) 
Treated with LLC-
GEN + EP (900 V, 2 
min) 
No. 
of 
tape 
strips 
Absorbance at Absorbance at Absorbance at Absorbance at Absorbance at 
1652 cm-
1 GEN 
1518 cm-
1 GEN 
1652 cm-
1 GEN 
1518 cm-
1 GEN 
1652 cm-
1 GEN 
1518 cm-
1 GEN 
1652 cm-
1 GEN 
1518 cm-
1 GEN 
1652 cm-
1 GEN 
1518 cm-
1 GEN 
1 0.06±0.03 0.05±0.02 0.05±0.05 0.04±0.04 0.04±0.01 0.03±0.00 0.15±0.02 0.12±0.02 0.22±0.10 0.18±0.08 
2 0.03±0.01 0.03±0.01 0.02±0.02 0.02±0.01 0.01±0.01 0.01±0.01 0.04±0.02 0.04±0.02 0.08±0.06 0.07±0.05 
3 0.03±0.02 0.02±0.01 - - 0.03±0.00 0,03±0.00 0.06±0.00 0.05±0.00 0.06±0.00 0.05±0.00 
4 - - - - 0.03±0.00 0.02±0.00 0.02±0.00 0.02±0.00 0.03±0.01 0.03±0.01 
5 - - - - - - 0.01±0.00 0.01±0.00 - - 
6 - - - - - - - - - - 
7 - - - - - - - - 0.02±0.02 0.02±0.01 
8 - - - - - - - - - - 
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5.2.3.5. Raman spectroscopy 
Mouse skin treated with LLC-GEN combined with EP was examined by Raman 
spectroscopy. The deeper skin penetration of LLC-GEN containing the ingredients CRH40 
and IPM was studied in Raman scattering experiments. Raman chemical mapping was 
employed to confirm the localization of GEN at various depths of the skin specimens. Since 
ATR-FTIR demonstrated that EP treatment at 900 V ensured deeper penetration than that at 
700 V, EP treatments at 900 V for 1 and 2 min were chosen for comparison with conventional 
treatment by Raman spectroscopy.  
Fig. 21 depicts the experimental Raman spectra of pure CRH40, IPM and GEN in the 
wavenumber range 2000–200 cm-1. As model solution, GEN was dissolved in CRH40 and 
IPM containing LLC (GEN content 3 wt.%) to observe the physical state of GEN. Six 
common characteristic ranges can be seen in the spectra of CRH40 and IPM, with peaks 
centered at 1733, 1442–1437, 1300, 1063 and 843–823 cm-1, and the spectra of CRH40, IPM 
and the LLC-GEN composition are very similar. Table 12 lists the Raman bands of the 
components and the LLC-GEN composition. The lipid components used in this study have 
similar chemical structures and therefore similar Raman bands.  
Figure 21. Experimental Raman spectra of CRH40 (a), IPM (b), LLC-GEN composition (c) 
and pure GEN (d). 
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Table 12. Observed Raman peaks and peak assignments of individual components and LLC-
GEN (str = stretching, def = deformation, tw = twisting). 
Assignment CRH40 IPM LLC-GEN GEN 
str C=O (ester) 1734 1733 1733 - 
str C=C (ring A)  - - 1648 1648 
str C=C (ring B) - - 1617 1617 
def CH2-CH3 1442 1437 1440 - 
str C=C - - - 1366 
 - - - 1319 
def CH2 and tw CH3 1300 1300 1300 - 
str C-C 1139 - - - 
  1079 1076 - 
str O-C 1063 1062 1063 1062 
str C=C and C-C-C 
(ring A) 
- - 991 991 
str C=C (ring A) and 
C-C-C (ring C) 
- - 887 887 
str C-CH (aromatic 
ring) 
843 - - - 
 - 823 824 - 
str C-C-C (C ring), str 
C=O 
- - 789 791 
str C-C-C and C=C 
(ring A) 
- 601 596 596 
str C-C-C (rings A and 
C) 
- - - 566 
The Raman spectrum of the LLC-GEN is basically the sum of the individual spectra, 
with minor shifts at around 1440 and 1079 cm
-1
 (Fig. 21c), indicating that the CH2-CH3 bonds 
of the LLC ingredients were affected by the interaction. Only a few Raman peaks of GEN 
were observed in the spectrum of LLC-GEN, at around 1617, 1062, 991, 887 and 789 cm
-1
. 
For GEN, two characteristic peaks, centered at 1617 and 789 cm
-1
, were assigned to the 
vibration of the C=C bond in ring B and the C-C-C, C-C and C=O bonds in ring C of the 
isoflavonoid molecule. These bands, free from interference from LLC ingredient bands, were 
chosen to confirm the localization of GEN in the skin specimen. 
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Raman spectra were acquired from skin treated with LLC-GEN and from non-treated 
intact ex vivo skin (Fig. 22), both perpendicular to the SC at equivalent depth (1000 µm). In 
the Raman spectrum of the treated skin, characteristic peaks of GEN and the LLC ingredients 
were observed at around 1670–1650 and 1470–1410 cm-1, respectively. The band of interest 
centred at 1440 cm
-1 
was assigned to the vibration of the amide functional group due to C=O 
stretching   and  –CH2, -CH3 bending of the skin lipid constituents.  The C=C stretching 
observed at 1617 cm
-1 
arose predominantly from the GEN isoflavonoid. The chemical 
mapping therefore confirmed the presence of the characteristic GEN band at around 1617   
cm
-1
. This peak is close to the vibrations of the native skin components. The skin component 
peaks at 1608 and 1453 cm
-1
 are well known to be associated with the C=C vibration of 
phenylalanine, the CH2 scissoring of lipids and the CH2, CH3 deformation of proteins in the 
native skin. 
Figure 22. Raman spectra of GEN-treated skin (900 V, 2 min, 1000 µm depth) (a), non-
treated skin specimen as control (1000 µm depth) (b), pure GEN (c) and GEN-free LLC 
composition (d) in the range 1900–1350 cm-1. 
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Fig. 23 displays qualitative distribution maps of the LLC components and GEN in 
animal skin specimens after different EP protocols, at 10-fold magnification. It was of interest 
to determine whether GEN diffusion is limited to the SC or to the epidermis or dermis. As 
discussed in the Materials and Methods section, as the skin specimens were planar, there was 
no need for the z-axis and adjustment of the depth values. 1300 µm deep sections of the skin 
specimen were investigated, from top to bottom corresponding to the SC  epidermis  
dermis. In order to confirm GEN diffusion, the chemical maps were resolved. The 
characteristic bands obtained for GEN at around 1617 cm
-1
 were used to visualize the spatial 
distribution of GEN from the Raman chemical mapping. The resolution of the chemical map 
and hence the identification of the ingredients present were achieved by using an MCR-ALS 
chemometric method. This method furnishes the response profiles of different components in 
complex samples, and provides information about the composition.  
Figure 23. Qualitative Raman maps of GEN distribution in animal skin specimens following 
different EP protocols (at 10-fold magnification). Conventionally treated skin as control (a), 
skin treated with EP at 900 V for 1 min (b) and skin treated with EP at 900 V for 2 min (c). 
Color coding of content: red > yellow > green > blue. 
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The presence of bands due to GEN and the LLC components in the upper layer of the 
skin (0–1000 µm) clearly indicates a good distribution following conventional treatment of 
the LLC-GEN composition (Fig. 23a). After the 900 V process for 1 min, GEN was 
accumulated in the middle section of the dermis (Fig. 23b). The penetration of GEN into the 
dermis was slowed by the dermis being a dense network of collagen fibers. The GEN and 
LLC component contents of the skin specimen (to a depth of 1300 µm) were relatively low 
after the 900 V EP process for 2 min (Fig. 23c), indicating that the GEN penetrated into the 
deep layer of the dermis. Although the difference between the EP processes for 1 and 2 min 
may seem minor, the slower diffusion of GEN may be presumed because of the enrichment of 
the LLC components (as vehicles of GEN) in the 1000–1300 µm deep section. In the absence 
of the EP process, the epidermal and upper dermal regions serve as a tight barrier, impeding 
deep GEN delivery. Thus, slow diffusion of the GEN took place.  
5.2.3.6. Effect of electroporation treatment on murine melanoma 
In each of the inoculated mice, the volume of the tumor was observed to be increased, to 
an extent directly proportional to the number of days of the examination. Tumors appeared on 
day 8 post-inoculation in both the treated and the untreated groups, with the exception of the 
mice in group F; in these mice, which were inoculated with B164A5 cells and treated with 
LLC-GEN and EP for 6 min at high voltage, the tumors appeared on day 10 post-inoculation. 
The mean tumor volume in group F was 83.33±28.86 mm3, in contrast with 466.66±208.16 
mm
3
 in group B, 589.78±204.67 mm3 in group C, 309.00±207.81 mm3 in group D and 
603.23±264.57 mm3 in group E. Comparison of the curves corresponding to the different 
treatment approaches reveals that the LLC-GEN formulation decreased the tumor volume, but 
following EP of this formulation, the results were even better. On day 21 of the experiment, 
the tumor volumes were 1001.58±409.26 mm3 in group B, 1000.86±404.96 mm3 in group C, 
866.66±256.58 mm3 in group D, 999.87±408.95 mm3 in group E and 751.00±151.03 mm3 in 
group F. Significant results (p ˂ 0.05) between the different experimental groups were found, 
as shown in Fig. 24. 
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Figure 24. Tumor volumes (mm
3
) in the different experimental groups on day 21 of the 
experiment. 
6. SUMMARY 
The main aim of my research work was to achieve a better understanding of the SC 
structure and its barrier function against drug penetration. I compared the unharmed SC in 
untreated psoriatic patients with that in the healthy control group.  A further goal was to 
investigate different methods of increasing the drug penetration through the skin.  
1. Using the components of the amide-I band, intact psoriatic skin was investigated to 
determine the changes in the secondary structure of the proteins by combining tape stripping 
and ATR-FTIR spectroscopy. FSD of the amide-I band was followed by curve-fitting to 
generate the underlying components. Integration of band areas provided an estimate of the 
secondary structure. 
To summarize this part of my Ph.D. work, new results were achieved:  
 The protein structure is changed on the unaffected area in psoriatic skin disease.  
 The results indicated decreases in all amide-I band components, the peak at  1660 
cm
-1
 revealing the most dramatic change. This peak is characteristic of the turn 
structure in the protein chain. The decrease is marked in the case of the β-sheet 
structure at 1630 cm
-1
 too.  
 The combination of tape stripping and ATR-FTIR spectroscopy could serve as an 
appropriate, rapid, simple noninvasive method for the study of psoriasis and give the 
possibility to follow up the efficiency of treatment. 
2. In the second part of my Ph.D. work, different types of transdermal drug delivery 
techniques were tested in order to increase the drug penetration through the skin.  
2.1.  IBU-containing hydrogels were used with SEs and TR as biocompatible penetration 
enhancers. The effects of the SE concentrations were examined through a synthetic membrane 
(in vitro) by the Franz cell method and the effects of SE hydrogel formulations on the skin 
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were evaluated by noninvasive in vivo tests. Furthermore, the behavior of these promising 
CPEs was tested through the use of two different skin test systems.  
 The SE concentration influenced the in vitro diffusion process markedly. SL showed 
the highest penetration effect at 6 wt.%. concentration, while SM presented the best 
enhancing effect at 0.5 wt.%. It is not useful to use these SEs at higher 
concentrations as CPEs.  
 The ex vivo and Skin PAMPA drug penetration results revealed that TR as cosolvent 
with SM significantly improved the penetration of the surfactant into the skin and 
promoted attainment of the maximum penetration effect. SM + TR could be a 
potential CPE combination for IBU in a dermally used hydrogel. 
 Skin PAMPA can serve as an effective and quick prediction model for the 
monitoring of CPEs and of drug penetration through the skin. The findings with the 
new artificial PAMPA membrane correlated closely with those with an ex vivo 
human skin membrane. 
 The in vivo results demonstrated that the incorporation of SEs (and especially SM) 
into a hydrogel extends and increases the hydration phenomenon. SM significantly 
improved the moisturizing effect of the hydrogel vehicle.   
2.2. Penetration of SLS was investigated combined with polyols. It was concluded from 
ATR-FTIR spectroscopy that the use of GLY and XYL can decrease SLS penetration. 
Different concentrations of GLY and XYL were studied and higher polyol treatments 
decreased the penetration of SLS to the deeper layers of the SC. 
2.3. A lamellar LLC was prepared in order to increase the solubility of the lipophilic 
phytocompound GEN. In order to verify the efficacy of this formulation, membrane diffusion 
and penetration studies were carried out with a Franz diffusion cell, through a synthetic 
membrane in vitro, a CAM ex ovo, and ex vivo excised human epidermis. Thereafter, LLC-
GEN was combined with EP to enhance the transdermal drug delivery. 
 The synergistic effect of EP was verified by in vivo ATR-FTIR and ex vivo Raman 
spectroscopy on hairless mouse skin. The penetration through the skin was ensured 
by the application of LLC-GEN alone. However, combination of the LLC 
nanocarrier system with EP resulted in rapid and more effective transdermal drug 
transport than that with the LLC-GEN formulation alone. 
 It was confirmed by murine melanoma investigations that EP could be a good 
method for the delivery of GEN because it delayed the appearance of the tumors and 
ensured the drug penetration to the deeper layers of the skin.  
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Psoriasis, one of the most common chronic inﬂammatory skin
diseases, with a frequency of approximately 1–2% of the population in
the developed world, is characterized by regular exacerbations of
cutaneous symptoms and frequent articular involvement. The prototypic
psoriatic skin lesions are sharply demarcated erythematous plaques
covered by silvery-white scaling, most often seen on the elbows, knees,
scalp, umbilicus and lumbar area. The diagnosis is usually made on
clinical grounds, though rarely a skin biopsy is necessary. The disease
has a polygenic inheritance, and the expression of the symptoms is
greatly inﬂuenced by environmental factors, such as stress or strepto-
coccal infections [1,2].
Histologically, the disease is characterized by keratinocyte hyper-
proliferation, lymphocyte and granulocyte inﬁltration of the epidermis
and dermis, and vasodilation of the dermal blood vessels. Hyperpro-
liferation of the keratinocytes results in highly perturbed functions of
the stratum corneum (SC). The SC, theuppermost layer of the epidermis,consists of keratin-rich anucleate nonviable cells (corneocytes) embed-
ded in an intercellular matrix of lipids [3]. It is well known that multiple
lipid bilayers play an important role in the permeability of the skin, and
psoriatic skin is more permeable than healthy skin [2]. A number of
studies have demonstrated that psoriatic skin exhibits alterations in
lipid metabolism [4,5], whereas the changes in the proteins and their
conformations in the SC of psoriatic skin have not been well studied
to date.
One of the most common applications of Fourier transform infrared
(FTIR) spectroscopy in protein studies is the analysis of secondary
structure. FTIR spectroscopy involves the measurement of the wave-
length and intensity of the absorption of IR radiation by a sample. The
amide-I band region (1700–1600 cm−1) is the spectral region most
sensitive to the secondary structural components of the proteins; this
is due very largely (approximately 80%) to the C_O stretch vibrations
of the peptide linkages. Fourier self-deconvolution (FSD), a band-
narrowingmethod, has not only enriched the qualitative interpretation
of IR spectra, but has also provided a basis for the semiquantitative
estimation of the secondary structure of proteins [6,7].
Attenuated total reﬂection FTIR (ATR-FTIR) spectroscopy is a tool
that is often used to characterize the lipids, proteins and water content
of the SC [8]. The sample is placed on an IR-transparent crystal, the IR
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Fig. 1.Theoriginal FTIR spectra of the SC and thedeconvolved and curve-ﬁtted components.
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internal reﬂectance creates an evanescent wave which penetrates into
the sample. Unlike the case of the KBr pellet method, this method
does not require sample preparation. We made use of the application
of an adhesive tape to obtain the spectrum of human SC in vivo [9].
The aim of the present paper is to give an account of the primary
results of an in vivo study of intact psoriatic skin, using the components
of the amide-I band to determine the changes in the secondary structure
of the proteins by combining tape stripping and ATR-FTIR spectroscopy.
2. Materials and methods
2.1. Experiments
Psoriatic SC samples were obtained from 6 untreated psoriatic
patients (3 males and 3 females) aged between 32 and 64. Normal
SC samples were collected from 20 healthy volunteers (10 males and
10 females) aged between 21 and 42 with no history of dermatological
disease. The study was approved by the local ethics committee
(Government Ofﬁce of Csongrád County Policy Administration Services
of Public Health, PSO-SPEKT-001). All volunteers were asked not to
apply any moisturizer or cosmetic product for at least 24 h before the
process. The forearm skin of each volunteer was strippedwith adhesive
cellophane tape; this was repeated up to 25 strips. In the case of the
psoriatic patients, the samples were taken from the unharmed skin of
the forearm. Every ﬁrst tape with one strip was discarded because of
the possibility of surface contamination. Every second adhesive tape
with three strips was analyzed, because this gave the most intensive IR
spectrum.
2.2. FTIR spectroscopy and curve-ﬁtting analysis
ATR-FTIR spectrawere recordedwith an Avatar 330 FT-IR spectrom-
eter (Thermo Nicolet, USA) equipped with a horizontal ATR crystal
(ZnSe, 45°), between 4000 and 400 cm−1, at an optical resolution of
4 cm−1. 128 scans were co-added and all spectral manipulations were
performed by using Thermo Scientiﬁc's GRAMS/AI Suite software. The
components of the amide-I band and their relative intensities were
estimated semiquantitatively in the 1695–1600 cm−1 region of the
FTIR spectra by a curve-ﬁtting algorithm using Gaussian–Lorenzian
mixing functions. The best ﬁts were found by an iterative process
minimizing the standard error.
2.3. Statistical analysis
The results of curve-ﬁttingwere evaluated and analyzed statistically
by Student's t-test. The data given are the averages of the results of
13 parallel (3 psoriatic and 10 healthy) experiments ± SD (p b 0.05*,
p b 0.01**).
3. Results and discussion
The amide-I band appears clearly in the ATR-FTIR spectrum of the
skin as a consequence of the coupling of the transition dipole moments
of the amide groups within the protein backbone. Various protein
secondary structures have their own characteristic amide-I bands. How-
ever, because of the strong overlap between the characteristic bands,
the amide-I bands of the recorded infrared spectra are too complex to
permit the direct determination of the components with various
secondary structures [10].
Band-narrowing procedures such as FSD and curve-ﬁtting greatly
enhance the potential of this band as a meaningful structural probe.
Such mathematical processes increase the degree of separation by
narrowing the half-bandwidths of the individual components for easier
visualizationwithout seriously distorting the spectrum. Themain disad-
vantage of this procedure is its tendency tomagnify both the signal andthe noise in the spectrum. This causes a dramatic increase in the
noise level, which necessitates coupling the FSD with a smoothing
function [6,11,12].
FSD of the corresponding ranges of the recorded spectra were used
to determine the approximate frequencies of the components of the
amide-I bands indicating the presence of protein chain sections with
various secondary structures [10,13]. Seven bands were ﬁtted to all
the spectra and their areas were compared (Fig. 1). The ratios of the
integrated band areas provide an estimate of the proportions of the
parts with various secondary protein structures.
A protein molecule is formed from a chain of amino acids. The
secondary structure of a protein is determined by the set of dihedral
angles (φ, ψ) which deﬁne the spatial orientation of the peptide
backbone, and the presence of speciﬁc hydrogen-bonds. Regular
secondary structures include α-helices and β-sheets. An ideal α-helix
has 3.6 residues per turn, and is built up from a contiguous amino acid
segment via backbone–backbone hydrogen-bond formation between
amino acids in positions i and i + 4. The residues taking part in an
α-helix have φ angles around−60° and ψ angles around−45°.
β-Sheets are created when atoms of β-strands are hydrogen-
bonded. β-Sheets may consist of parallel strands, antiparallel strands
or a mixture of parallel and antiparallel strands. In parallel β-sheets
the strands run in one direction, whereas in antiparallel sheets they
run in alternating directions. The dihedral angles of the β-sheet are
φ ~ −130° and ψ ~ −120°, forming an extended structure with
some right-handed twist.
Turns allow a protein to fold back on itself and are stabilized by a
hydrogen-bond that holds the ends together. They are classiﬁed
according to the number of residues involved in the hydrogen-bonded
structure. Unordered structure is generally deﬁned as a conformation
that is not helix, sheet or turn [13].
In the SC, greater ﬂexibility is achieved through loose packing of the
keratin ﬁlaments and a lower number of disulﬁde crosslinks. It was
observed that the overall intensities of the amide-I bands were lower
for the psoriatic SC than for the healthy SC (Fig. 2), but the peak at
1660 cm−1 exhibited the most pronounced alteration, as shown in
Fig. 3. The proteins in the SC are mainly in α-helical conformation
[14]. The peak at 1650 cm−1 indicates the presence of an α-helix
(Fig. 3), which always has the largest area. We focused on the peak at
1660 cm−1, characteristic of the turns in the protein chain [13]. The
intensity of this peak decreases almost to zero in psoriatic patients,
indicating the drop in concentration in the turn protein regions
(Table 1). We have given the results for men and women separately,
because of the differences in skin between the genders [15].
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185B. Balázs et al. / Microchemical Journal 117 (2014) 183–186Fig. 4 compares the areas of the peak at 1660 cm−1 for the healthy
control group and the psoriatic patients. As a result of the presence of
psoriasis, the intensity of this band is signiﬁcantly lower for both
males (p b 0.05*) and females (p b 0.01**). The areas of all the amide-I
band components are less in the psoriatic group, but the decrease is
especially marked in the cases of the bands at 1630 and at 1660 cm−1
(Fig. 3). The former is in the middle of the region characteristic of the
β-sheet structure, and the latter reﬂects the turn structure. The fall in
the intensity of the latter suggests the loss of those parts of the protein
structure even in the unharmed psoriatic SC which provide the protein
with ﬂexibility.4. Conclusions
The protein structure is changed on the unaffected area in the psori-
atic skin disease. The combination of tape stripping and ATR-FTIR spec-
troscopy could serve as an appropriate, rapid, simple noninvasive
method for the study of psoriasis and for follow-up of the efﬁciency of
treatment. From a pharmaceutical technology aspect, these results sug-
gest the development of a targeted dermal system which ensures con-
venient treatment to unaffected areas of the psoriatic skin. However,
further investigations with higher numbers of patients are needed in
order to reﬁne the method and to gain deeper insight into the nature
of psoriasis itself.
Table 1
Decreased integrated area of amide-I protein structures in psoriatic skin.
Conformation β-sheet α-helix Turns β-sheet Turn
Wavenumber [cm−1] 1620 1640 1650 1670 1680 1630 1660
Healthy men mean integrated area (±SD) 0.28 (0.11) 0.96 (0.24) 1.85 (0.58) 0.62 (0.15) 0.18 (0.14) 0.32 (0.25) 0.36 (0.17)
Psoriatic men mean integrated area (±SD) 0.07 (0.04) 0.28 (0.24) 0.54 (0.30) 0.16 (0.12) 0.05 (0.02) 0.04 (0.005) 0.03 (0.03)
Integrated area percentage (%) of psoriatic over healthy 24.6 29.4 29.3 25.9 29.3 13.2 9.2
Healthy women mean integrated area (±SD) 0.12 (0.10) 0.62 (0.14) 1.27 (0.52) 0.34 (0.16) 0.14 (0.03) 0.20 (0.10) 0.23 (0.06)
Psoriatic women mean integrated area (±SD) 0.07 (0.02) 0.29 (0.01) 0.55 (0.19) 0.23 (0.06) 0.05 (0.03) 0.08 (0.04) 0.02 (0.01)
Integrated area percentage (%) of psoriatic over healthy 64.4 47.4 43.1 67 33.9 3.9 9.7
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Pro-apoptotic Effect of Soy Total Extract Incorporated
in Lyotropic Liquid Crystals Formulation
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The paper  aims  to test the pro apoptotic capacity of soy total extract on  the B164A5 mouse  melanoma cells
alone and after incorporation in the modern formulation lyotropic liquid crystals. DAPI dye and Annexin-FITC-
7AAD double staining show that soy extract present both early and late apoptotic properties against B164A5
murine melanoma cell line. Furthermore , incorporation of soy extract in the modern formulation does not
affect in a negative manner this property. As explained in the paper the benefits of such an approach, this
preliminary study represent an obvious proof that incorporation of soy extract in this new formulation is a
good option for furtherer in vivo studies on animal model of melanoma.
Keywords: soy extract, lyotropic liquid crystals, murine melanoma, apoptosis
Among the modern  formulations used in the
pharmaceutical field for local administration of different
active agents,  lyotropic liquid crystals (LLC) have gained
increased attention due to their special physico-chemical
properties [1,2] . As a brief description of the formulation-
LLC are formed by surfactants having two different parts:
a non polar, seldom hydrocarbon tail and a polar, seldom
ionic, head [3].  LLC have the properties somewhere in
between a conventional liquid and a solid crystal [4]. They
have the ability to exhibit phase transitions depending on
the temperature and on the concentration of the liquid
crystals in the employed solvent which is frequently water
[5]. The thermodynamic stability of these formulations  and
the intense similarity  of these systems to those in living
organism makes LLC a great excipient  for the local
administration of  different active agents [6,7].
Pure natural compounds or plant total extract represent
a wellspring of remedies for a variety of pathologies. During
the past decades a spectacular  number of remedies from
nature turned in classical therapy, well accepted by an
increasing number of patients. An intensively and
controversy studied extract is represented by soy extract,
respectively its activate isoflavones genistein and daidzein.
Recent studies show that soy total extract induce apoptosis
in prostate cancer cells [8]. Furthermore it  shows anti
menopause effects[9] . It has been show that soy extract
is more potent than genistein on an animal model of breast
cancer on tumor growth inhibition [10]. It has been reported
its antiproliferative activity in a mouse model of skin cancer
[11].Soy isoflavones have been studied for their ant diabetic
and hypolipidemic effects [12]. The group of Catania et al.,
have published that in case of ovariectomized rats orally
administered soy extract improves the endothelial
dysfunction [13] . Soy germ extract have been proofed pro
apoptotic properties in vitro in case of colon cancer [14] .
The paper represents a preliminary study of the soy
based formulation for furtherer in vivo investigations on
animal models of melanoma . It aims  to test the pro
apoptotic capacity of soy extract employing the B164A5
*  email: claudiumorgovan@yahoo.com              # equal contribution
mouse  melanoma cells alone and after incorporation in
the modern lyotropic liquid crystals formulation.
Experimental part
Materials and methods
Extraction
Soy seeds were kindly provided from University of
Agricultural Sciences and Veterinary Medicine, Timisoara,
Romania, Department of Plant Culture. As previously
described hydroalcoholic extracts were performed. Dry
soybeans were put into powder. A  hydroalcoholic solvent
containing 70% ethanol was prepared. 10% vegetal product
extracts were ultrasonicated for 10 min in the ultrasonic
bath . Afterwards the solvent was evaporated and the
powder was used for furtherer experiments [15].
Lamellar lyotropic liquid crystalline soy extract based
formulation
Soy extract, the active agent was incorporated in the
lamellar lyotropic liquid crystal formulation in a
concentration of 10%. The carrier was the mixture of a
non-ionic surfactant, Cremophor RH40 (Polyoxyl 40
Hydrogenated Castor Oil USP/NF). It was obtained from
BASF (67056, Ludwigshafen, Germany). The water phase
of the systems was purified water (Ph.Eur.6.), while the oil
phase was isopropyl myristate (Merck Kft. 1121, Budapest,
Hungary). The oil-surfactant mixture (oil:surfactant ratio
= 2:1) was homogenized with a magnetic stirrer at room
temperature. Then 10% of water was added to this mixture
in small amounts while stirring. The 10 % soy extract  was
incorporated in the oil-surfactant mixture with a magnetic
stirrer.
DAPI (4, 6-Diamidino-2-phenylindole) staining
B16 cells were seeded at a concentration of 5x104 in a
chamber slide system formed of 8 well glass slides in
culture medium. After 24h cells were incubated in medium
containing 10%FCS and 200μg/mL of soy extract,
respectively  200μg/mL of soy extract corresponding to
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the 10% lamellar lyotropic liquid crystalline formulation.
The total volume added in chamber was 400  μL. Cells
were incubated for 72 h and afterwards the medium was
removed. Cells were washed with PBS and afterwards
400μL of staining solution were added in each well. The
staining solution consisted of a mixture of methanol and
DAPI (Roche) as follows: 1 mL methanol: 2  μL DAPI (from
a stock solution of 1mg/mL). Cells were incubated for 5
minutes with this staining solution and afterwards washed
with PBS and analyzed by fluorescence microscopy.
Annexin-FITC-7AAD double staining
Cells were cultivated in a 6 well plates at a density of
80% using normal medium. After 24h medium containing
10% FCS and and 200 μg/mL of soy extract, respectively
200 μg/mL of soy extract corresponding to the 10% lamellar
lyotropic liquid crystalline formulation were added. After
48h cells were detached using trypsin, washed with ice
cold PBS and resuspended in 500 μLAnnexin binding buffer
(1.19 g HEPES NaOH pH =7.4; 4.09 g NaCl; 0.138 g CaCl2
in 50 mL distillated water and diluted 1:10) at a
concentration of 1x106 cells/mL. Cells were centrifugated
5 min at 1200 rpm, the supernatant was discarded and the
cells were resuspended in 70 μL of Annexin binding buffer.
5  μL Annexin V-FITC (ImmunoTools) and 5 μL 7AAD
(ImmunoTools) were added and cells were incubated 15
min on ice and in the dark. Samples were measured by
FACS on FL1 and FL3 fluorescence channels using a BD
Canto II FACS DIVA device. Flow Jo soft (7.6.3) was used
for data analysis.
Statistics
One Way ANOVA followed by Bonferroni post test were
used to determine the statistical difference between various
experimental and control groups.*, ** and *** indicate
p<0.05, p<0.01 and p<0.001 compared to control group.
Results and discussions
The balance between proliferation and apoptosis has a
vital role in many human diseases including cancer [16].
Among years different approaches have been conducted
in order to fight cancer and one important strategy points
towards  finding  pro-apoptotic agents [17].  DAPI staining
is frequently used as a preliminary assay to test the pro-
apoptotic capacity of different active agents [18] . After a
period of incubation of 72h with 200μg/mL of soy extract,
respectively 200μg/mL of soy extract corresponding to the
10% lamellar lyotropic liquid crystalline formulation, cells
stained with DAPI displayed the typical characteristics of
cells undergoing apoptosis (fig. 1). The blue stained
nucleus allows to notice the morphological hallmarks of
apoptosis: nuclear fragmentation, chromatin
condensation, nuclear condensation as a sign of loss of
cell membrane integrity, reduction of cellular volume,
rounding up of the cell. It can not be detected a significant
difference regarding the morphological signs of apoptosis
between soy extract respectively the soy extract
corresponding to the 10% lamellar lyotropic liquid
crystalline based formulation. This aspect represent a good
news for furtherer in vivo investigations, meaning that the
formulation does not affect the biological activity of soy
extract, but it helps, as explained in the introduction to its
delivery. In addition it can be observed that after the 72 h of
incubation both the extract respectively the extract
incorporated in the formulation present also anti-
proliferative effect, as it can be noticed by the decreased
number of cells presented in a specific field. DAPI staining
was previously used in order to test the pro-apoptotic
activity of genistein, the most active isoflavone in soy
extract, on human uterine leiomyoma, human prostate
carcinoma PC-3 cells, Ewing’s sarcoma CHP-100 cells,
breast cancer  MCF-7 cells [19-21].a
In order to be able to get more data about the apoptotic
process, the double staining Annexin-FITC-7AAD was
performed. This assay allows to get information about early
apoptotic, late apoptotic and necrotic cells after incubation
to different active agents [22] . Results  show (fig. 2), that
after a period of incubation of 72 h both the soy extract
alone, respectively incorporated in the LLC formulation
present early and late apoptotic properties. Average value
corresponding to three different experiment show
3.38±2.89 early apoptotic cells in case of incubation with
200 μg/mL of soy extract  and  2.60±0.84 early apoptotic
cells in case of incubation with 200 μg/mL of soy extract
incorporated in the LLC formulation. The tested active
agents succeeded to induce more intense the phenomena
of late apoptosis, as it can be depicted from figure 2, namely
Fig. 2. Annexin-FITC-7AAD double  staining after 72h incubation of B164A5 cells with: a) Medium; b) 200μg/mL of soy extract; c) 200μg/mL of
soy extract corresponding to the 10% LLC soy extract based formulation
Fig. 1. DAPI staining after 72h
incubaton of B164A5 cells
with a) Medium; b) 200ìμg/mL
of soy extract c) 200ìμg/mL of
soy extract corresponding to
the 10% LLC formulation
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24.52±1.69  late apoptotic cells in case of incubation with
200μg/mL of soy extract and  22.66±3,34 late apoptotic
cells in case of incubation with 200μg/mL of soy extract
incorporated in the LLC formulation. A decreased number
of necrotic cells could  be also detected,  namely  0.613
±0.36 necrotic cells in case of incubation with 200 μg/mL
of soy extract and 0.987±0.11 late apoptotic cells in case
of incubation with 200μg/mL  of soy extract incorporated
in the LLC formulation. The pro-apoptotic capacity of soy
extract was also described in case of prostate cancer cells,
human AGS gastric cancer cells [8,23]. Soy isoflavones,
the most active phytocompounds, as we previously
discussed showed pro-apoptotic effect in case of breast
cancer cells,  murine and human bladder cancer cells, HT-
29 colon cancer cells, human prostatic cancer cell line
LNCaP,  human hepatoma cell lines HepG2, Hep3B, Huh7,
PLC, and HA22T [14.24.27].Furthermore, a recent study
shows  that the biotransformed soy extract fermented by
Aspergillus awamor  induces apoptosis in case of A375
human  melanoma cell line [28]. Correlating to the data
existing in the literature this study brings in to light the pro-
apoptotic activity of soy extract on the murine melanoma
B164A5 cell line.
Conclusions
Results show that soy extract present apoptotic
properties against B164A5 murine melanoma cell line.
Furthermore , incorporation of soy extract in the modern
formulation lamellar lyotropic liquid crystals does not affect
in a negative manner this property. As explained in the
introduction the benefits of such an approach, this
preliminary study represents an obvious proof that
incorporation of soy extract in this new formulation is a
good option for furtherer in vivo studies on animal model of
melanoma
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Abstract: A lamellar lyotropic liquid crystal genistein-based formulation (LLC-Gen) was 
prepared in order to increase the aqueous solubility of the lipophilic phytocompound 
genistein. The formulation was applied locally, in a murine model of melanoma, with or 
without electroporation. The results demonstrated that, when the formulation was applied by 
electroporation, the tumors appeared later. During the 21 days of the experiment, the  
LLC-Gen formulation decreased the tumor volume, the amount of melanin and the degree 
of erythema, but when electroporation was applied, all these parameters indicated a better 
prognosis even (lower tumor volume, amount of melanin and degree of erythema).  
Although hematoxylin–eosin (HE) staining confirmed the above events, application of the 
LLC-Gen formulation by electroporation did not lead to a significant effect in terms of the 
serum concentrations of the protein S100B and serum neuron specific enolase (NSE), or the 
tissue expression of the platelet-derived growth factor receptor β (PDGFRβ) antibody. 
Keywords: genistein; lyotropic liquid crystals; electroporation; murine melanoma 
 
1. Introduction 
The most recent statistics regarding new melanoma cases in Europe show that an average of 47.2 males 
and 53.1 females per 100,000 investigated subjects were diagnosed with melanoma in 2012 [1]. The 
incidence varies within the countries of the European Union, with very high rates registered in 
Switzerland, Denmark, and Norway as compared with Greece, Bulgaria, Cyprus and Romania [2,3]. 
Melanin pigmentation in mammalian skin is under complex regulatory control by several pathways triggered 
by receptor-dependent and -independent mechanisms, hormonal, auto-, para-, or intracrine manner [4]. As 
the incidence of melanoma is increasing worldwide, researchers are investing considerable amounts of 
time and money in the search for an effective treatment for this dangerous disease [5–7]. However there 
is no reliable therapy for metastatic melanoma despite the progress made in the field [8]. 
Natural compounds, and especially plant secondary metabolites, have been studied for centuries for 
their complex therapeutic benefits [9]. Different types of cancer have revealed positive responses to 
certain natural compounds both in vitro and in vivo. Genistein (Gen) is a naturally occurring compound 
in the class of isoflavonoids. It is well known for its estrogeno-mimetic properties [10]. It has been 
intensively studied in cases of breast and prostate cancer [11,12]. Its efficacy has been shown in 
malignant melanoma. In an earlier study we observed that Gen decreases the tumor size, the metastasis 
potential and the level of melanization in a B16 mouse model of melanoma. However, the recovery of 
the skin lesions was impaired [13]. Those data led us to propose another approach to promote the 
recovery of murine melanoma lesions: electroporation of a lyotropic liquid crystal Gen-based 
formulation (LLC-Gen). 
Lyotropic liquid crystal systems (LLC) have recently received increased attention in both the 
cosmetic and pharmaceutical fields [14]. They flow like liquids (hence the name liquid crystals) and in 
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part maintain the ordered structure of crystalline solids [15]. The advantageous qualities of such 
formulations include their amphiphilic nature, the similarity to colloidal systems existing in living 
organisms, the various structures of liquid crystal states, and their thermodynamic stability [16]. Gen is 
a lipophilic compound that is practically insoluble in water, which can be a real problem in terms of 
formulation and bioavailability. LLCs display good solubilizing effects, sustained release and enhanced 
bioavailability of other lipophilic drugs [17]. 
We decided to attempt a new approach by applying this new LLC-Gen formulation locally with or 
without electroporation, a process characterized by structural changes in the cell membrane barrier and 
resulting reversible increase in transmembrane transport; practically, aqueous pores are created in lipid 
bilayers. These transitory changes, possible due to the application of high-voltage pulses, can be used  
to load different molecules into the cells [18,19]. Primarily designed for gene transfer, electroporation  
is nowadays used for a wide range of structures, such as antibodies, oligonucleotides, DNA, ions,  
drugs, etc. [20]. 
Thus, the aims of this study were to investigate whether lamellar LLC systems form a good base for 
Gen incorporation, and to analyze the effects of electroporation with such a formulation in a murine 
model of melanoma. 
2. Results and Discussion 
2.1. Polarization Microscopic Examinations 
In the development of the dermal delivery, we prepared a LLC formulation that is able to suspend 
Gen at a concentration of 3%. 
Figure 1 presents a polarized microscopic picture of the developed LLC structure, revealing a lamellar 
LLC pattern with a characteristic ribbon structure in polarized light. 
 
Figure 1. Polarizing microscopic examination of blank lyotropic liquid crystal systems 
(LLC) at a magnification of 20×. 
2.2. Rheological Investigations 
The characteristics of the LLC system include the frequency-dependent storage and loss moduli.  
In the investigated frequency range, the blank LLC system is more elastic than viscous. The solubilization 
of Gen in the LLC system led to a consistency increase (Figure 2). 
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Figure 2. Rheological characterization of the blank and Genistein (Gen)-containing LLC formulations. 
Melanoma was induced and the formulation was applied as indicated in the Experimental Section.  
In each of the inoculated mice, the volume of the tumor was observed to be increased, to an extent 
directly proportional to the number of days of the examination. Tumors appeared on day eight  
post-inoculation in both the treated and the untreated groups, with the exception of the mice in group F; 
in these mice, which were inoculated with B164A5 cells and treated with LLCs containing 3% Gen and 
electroporated for 6 min at high-voltage, the tumors appeared on day 10 post-inoculation. The mean 
tumor volume in group F was 83.33 ± 28.86 mm3, in contrast with 466.66 ± 208.16 mm3 in  
group B, 589.78 ± 204.67 mm3 in group C, 309.00 ± 207.81 mm3 in group D and 603.23 ± 264.57 mm3 
in group E. Comparison of the curves corresponding to the different treatment approaches reveals  
that the LLC-Gen formulation decreased the tumor volume, but following electroporation of this  
formulation, the results were even better. On day 21 of the experiment, the tumor volumes were  
1001.58 ± 409.26 mm3 in group B, 1000.86 ± 404.96 mm3 in group C, 866.66 ± 256.58 mm3 in group 
D, 999.87 ± 408.95 mm3 in group E and 751.00 ± 151.03 mm3 in group F. Significant results (p ˂ 0.05) 
between the different experimental groups were found as shown in Figure 3. 
 
Figure 3. Tumor volumes (mm3) in the different experimental groups on day 21 of the 
experiment. ** p < 0.01, *** p < 0.001. 
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During the 21 days of the experiment, noninvasive measurements of relative melanin pigmentation 
and the degree of erythema were performed every two days with the Courage-Khazaka Mexameter®  
MX 18 Multiprobe Adapter System (MPA5). Curves corresponding to relative melanin pigmentation  
were plotted and differences relative to the blank group A were recorded starting from day five  
post-inoculation. The normal amount of melanin in the skin of the C57BL6J mouse varies in the interval 
635–670 arbitrary units (A.U.). On day five post-inoculation, the interval increased to 695–720 A.U. 
Differences between the experimental groups in the amount of relative melanin pigmentation were 
observed on day 9: 645 ± 14 A.U. in group A, 789 ± 60 A.U. in group B, 788 ± 19 A.U. in group C,  
752 ± 5 A.U. in group D, 782 ± 12 A.U. in group E and 735 ± 28 A.U. in group F. The curves presented 
in Figure 4 show that application of the LLC-Gen formulation to the skin resulted in a slight decrease  
in the amount of melanin, but when the formulation was applied by electroporation the level of 
pathological melanin was reduced significantly. On day 21 of the experiment, the results were  
650 ± 13 A.U. in group A, 901 ± 21 A.U. in group B, 909 ± 17 A.U. in group C, 851 ± 28 A.U. in  
group D, 879 ± 45 A.U. in group E and 826 ± 36 A.U. in group F. Significant differences (p ˂ 0.05) 
between the different experimental groups were found as shown in Figure 4. 
 
Figure 4. Melanin amounts (in arbitrary units (A.U.) as determined by the manufactured 
device) in the different experimental groups on day 21 of the experiment. * p < 0.05,  
** p < 0.01. 
The MX18 device was also employed to determine the degree of erythema after the appearance of 
the tumors and to observe any changes that occurred after treatment. The normal values for the skin of 
the C57BL6J mouse are in the range 50–60 A.U. Increased levels, corresponding to erythema, were 
observed from day nine post-inoculation. The recorded levels on day nine were 58 ± 2 A.U. in  
group A, 218 ± 26 A.U. in group B, 210 ± 16 A.U. in group C, 192 ± 28 A.U. in group D,  
214 ± 21 A.U. in group E and 161 ± 23 A.U. in group F. The LLC-Gen formulation proved to diminish 
the degree of erythema slightly, but when electroporation was applied the LLC-Gen formulation acted 
more effectively. On day 21 of the experiment, the levels were 59 ± 3 A.U. in group A, 228 ± 14 A.U. 
in group B, 215 ± 4 A.U. in group C, 183 ± 14 A.U. in group D, 228 ± 3 A.U. in group E and  
152 ± 9 A.U. in group F. Significant results (p ˂ 0.05) between the different experimental groups were 
found as shown in Figure 5. 
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On day 21 of the experiment, blood was collected from the mice in all groups and the serum 
concentrations of the protein S100B (µg/L) (a highly specific melanoma marker) and of neuron specific 
enolase (NSE) (ng/L) were determined. The mean concentrations of S100B in the different experimental  
groups were 0.55 ± 0.35 µg/L in group A, 0.96 ± 0.18 µg/L in group B, 0.86 ± 0.56 µg/L in group C, 
0.510 ± 0.36 µg/L in group D, 0.690 ± 0.28 µg/L in group E and 0.54 ± 0.28 µg/L in group F.  
Higher values than the control were observed in the groups inoculated with melanoma cells. Although 
the mean values were slightly lower when electroporation was applied, the LLC-Gen formulation did 
not have a significant effect on the serum S100B concentration (Figure 6). The mean concentrations of  
NSE in the different experimental groups were 4.0 ± 1.4 ng/L in group A, 9.2 ± 3.0 ng/L in group B,  
9.0 ± 5.1 ng/L in group C, 7.9 ± 5.6 ng/L in group D, 9.8 ± 8.3 ng/L in group E and 6.0 ± 2.8 ng/L in 
group F. Again, levels higher than the control were observed in the groups inoculated with melanoma 
cells. Although the mean NSE levels were slightly lower when electroporation was applied, the  
LLC-Gen formulation did not have a significant effect in reducing this marker either (Figure 7). 
 
Figure 5. Erythema (in A.U. as determined by the manufactured device) in the different 
experimental groups on day 21 of the experiment. * p < 0.05, *** p < 0.001. 
 
Figure 6. Serum concentrations of the protein S100B (µg/L) in the different experimental 
groups on day 21 of the experiment. 
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Figure 7. Serum neuron specific enolase (NSE) concentrations (ng/mL) in the different 
experimental groups on day 21 of the experiment. “ns” indicates not-significant. 
2.3. Histological and Immunohistochemical Results 
Conventional hematoxylin–eosin (HE) analysis revealed similar features in groups B and C, with 
moderate to intense pigmentation in almost all the tumor cells (Figure 8a,b). In group D, weak 
pigmentation was observed in isolated cells (Figure 8c). Group E was characterized by moderate 
pigmentation with intense pigmentation in a few nests of tumor melanocytes (Figure 8d). Group F 
exhibited similarities with group D, with a general feature of a lower level of pigmentation and with 
melanin present in a few tumor cells (Figure 8e). 
 
Figure 8. Hematoxylin–eosin (HE) staining in the different groups with skin melanoma: 
(a,b): groups B and C with moderate to intense pigmentation in almost all the tumor cells; 
(c): group D, exhibiting melanoma with weak and isolated pigment; (d): group E, displaying 
moderate pigmentation, with intense pigmentation in a few nests of tumor melanocytes;  
(e): group F, with the presence of melanin in isolated cells. Magnification: 40×; scale bar: 
200 μm. 
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In the case of platelet-derived growth factor receptor β (PDGFRβ) immunostaining only a mild 
intratumoral reaction was seen in the peritumoral stromal myofibroblasts (Figure 9a,b) and in the tumor 
cells (Figure 9c), independently of the nature of the groups. 
 
Figure 9. Representative pictures of platelet-derived growth factor receptor β  
(PDGFRβ)-immunostaining. Only a mild intratumoral reaction is seen in the peritumoral 
stromal myofibroblasts (a,b) and in the tumor cells (c), independently of the nature of the 
groups. Arrows and arrowheads highlight peritumoral stromal cells and intratumoral positive 
tumor cells, respectively. Dacarbazine red reaction; optical scanning microscopy—OM 200×. 
2.4. Discussion 
Polarization microscopy can be used for the examination and identification of the LLC system.  
The behavior of light in crystalline materials depends on its direction relative to the crystal structure. 
Unlike isotropic materials which are invisible between the crossed polarizers of a polarization 
microscope, a thin sample of LLC in the same experimental arrangement yields a typical picture  
(called texture) which shows the effective positional birefringence of the system [21]. 
Oscillating rheological measurements offer a convenient possibility for identification of the lamellar 
phase in dermal and transdermal drug delivery systems [22]. The viscoelastic properties are indicated by 
the changes in the elastic storage modulus (G′), and the viscous loss modulus (G″), as a function of 
frequency. The G′, which defines the energy stored per unit volume, is proportional to the elastic property 
of the sample, whereas the G″ is the energy dissipated per unit volume, proportional to the viscous 
component of the sample [23,24]. It is clear from Figure 2 that the blank LLC composition demonstrates 
more elastic than viscous behavior. The incorporation of Gen led to increases in G′ and G″, with 
maintenance of LLC state. 
Gen has previously been described as a phytocompound active on melanoma, both on different cell 
lines in vitro and on various murine models in vivo [25–28]. An half maximal inhibitory concentration 
(IC50) of 12.5 µM has been reported after seven days of incubation in the case of the B164A5 cell line 
for the induction of angiogenesis and the inhibition of solid tumors when the cell line was implanted in 
C57BL6J mice, at a rate of 30%–50% (depending on the mode of administration) [13,29,30]. The present 
study involves a new approach toward the recovery of murine melanoma lesions: electroporation of  
an LLC-Gen formulation. This approach combines a new local formulation and a new mode of 
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administration for Gen. To the best of our knowledge, the effect of the local administration of a  
Gen-based formulation on murine melanoma has not been reported previously. We chose this 
combination because LLCs have been intensively studied as carrier systems for lipophilic drugs with  
a view to increasing the dermal penetration [14,31,32], and because electroporation increases the 
cutaneous penetration of various active agents [33–35]. We used polarizing microscopy and rheological 
investigations to confirm that this system was a lamellar LLC. 
Our first important observation was that the tumors appeared two days later in the mice treated with 
LLC with 3% Gen and electroporated for six minutes at high-voltage than in the untreated or the 
normally treated mice. The second important observation was that the locally applied formulation 
decreased the tumor volume to an extent proportional to the number of days of treatment, and when 
electroporation was applied, the effect was increased. 
Experimental data suggest that the degree of skin pigmentation correlates directly with the amount of 
melanin [36]. However, the measurement of skin pigmentation is not a perfectly reliable method to 
determine the exact melanin content but it indicates the relative melanin pigmentation, as a prediction 
value [4,37]. The decrease in skin pigmentation can reflect with certain limitation the decrease of 
melanin content reflecting the inhibition of melanogenesis, as a secondary effect. Substantial evidence 
indicates that the inhibition of melanogenesis has a therapeutic effect [38–41]. The presence of melanin 
pigment or the presence of an active melanogenesis can alter the sensitivity and behavior of melanoma 
cells to chemoimmunotherapy [38,39], thus the inhibition of melanogenesis can represent a therapeutic 
target. Melanin measurement with the Mexameter MX18 in physiological or pathological cases, with  
or without treatment is a noninvasive method currently used in skin research [42–45]. The level of 
melanin in the mice treated with LLCs with 3% Gen and electroporated for 6 min at high-voltage was 
significantly decreased. The same held for the extent of erythema, a skin disorder that occurs with any 
skin lesion [13]. Melanoma is one of the most severe skin lesions [46]. 
After the noninvasive measurements, blood was collected in order to determine the concentrations in 
the different experimental groups of two melanoma markers: S100B and NSE. S100B is a 21-kDa 
protein that plays a role in preserving the cytoskeletal integrity, migration, cell cycle regulation and 
apoptosis [47]. Elevated S100B serum levels have been found in advanced stages of melanoma and have 
been associated with tumor progression and a shorter survival [48]. In contrast with S100B, NSE has 
been reported to be elevated in the early stages of melanoma [49]. Our results revealed decreased serum 
concentrations of both selected markers in mice treated with LLCs with 3% Gen and electroporated  
for 6 min at high-voltage as compared with the untreated mice, but the results were not statistically 
significant (p ˃ 0.05). 
The PDGFRs are members of a family of tyrosine kinase receptors found on the surface of cells.  
They regulate important processes such as cell differentiation, proliferation, growth and development [50]. 
There are two forms, encoded by different genes, PDGFRα and PDGFRβ [51]. PDGFRβ is normally 
present in cells of mesenchymal origin, e.g., vascular endothelial cells, fibroblasts, bone marrow cells 
and monocytes [52]. However, its expression is upregulated in the event of imbalances such as 
atherosclerosis, fibrosis and cancer [50]. B16 murine melanoma cells express PDGFRβ in the tumor 
microenvironment and the tumor stroma [53,54]. We therefore checked its expression after local Gen 
treatment with or without electroporation. The results showed that there was no marked difference in 
expression profile between the groups. Recent studies have shown that, in the case of the vascular smooth 
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muscle, isoflavone inhibits PDGF-stimulated proteoglycan synthesis without blocking PDGFRβ 
phosphorylation [55]. Additionally, Gen did not affect early signal transduction through PDGFRβ in 
primary cultured rat aortic smooth muscle cells [56]. We can now report that Gen did not affect the 
expression of PDGFR and PDGFRβ in B16 murine melanoma. 
3. Experimental Section 
3.1. Materials 
Gen was from Extrasynthèse (Genay, France; purity > 95%), and the mouse adherent melanoma cell 
line B164A5 was purchased from the European Collection of Cell Cultures (ECACC) (Salisbury, UK). 
The cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10%  
heat-inactivated fetal calf serum (FCS), 1% non-essential amino acids and 1% penicillin-streptomycin 
in a humidified atmosphere containing 5% CO2 at 37 °C. All cell culture media and supplements were 
from Life Technologies (Paisley, UK). In the preparation for injection, cells were trypsinized, counted 
with the aid of trypan blue, washed with PBS, resuspended at 1 × 106 cells/0.1 mL in saline solution and 
injected immediately, as described below. 
3.2. Lamellar Lyotropic Liquid Crystal Genistein (LLC-Gen) Formulation 
The lamellar LLC formulation was developed because this crystal structure demonstrates the greatest 
similarity to the lipid bilayer of the skin [57]. Three percent of Gen was incorporated as active agent. 
The carrier was a mixture of a non-ionic surfactant, Cremophor RH40 (Polyoxyl 40 Hydrogenated Castor 
Oil USP/NF), obtained from BASF (Ludwigshafen, Germany). It is tolerated well by tissues and has low 
toxicity, and its HLB (hydrophilic-lipophilic balance) value is 14–16. The aqueous phase of the systems 
was purified water (European Pharmacopoeia 6th Edition), while the oil phase was isopropyl myristate 
(Merck, Budapest, Hungary). 
A Gen-free LLC was prepared by the following procedure. The oil-surfactant mixture (oil:surfactant 
ratio = 2:1) was homogenized with a magnetic stirrer at room temperature. Ten percent of water was 
then added in small amounts to this mixture during stirring. A similar composition was prepared by using 
Gen, and the 3% of Gen was incorporated in the oil-surfactant mixture with a magnetic stirrer. 
3.3. Electroporation Parameters 
The Mezoforte Duo Mez 120905-D was provided by the Derm Clinic of Anti-Aging Dermatology, 
Aesthetic Laser and Plastic Surgery (Budapest, Hungary). The device operates on the basis of a pulsed 
electromagnetic field. The polypropylene-covered treating handpiece contains a 25 mm diameter plate 
electrode. Modulation was achieved with 1800 V high-voltage pulses with a voltage pulse duration of  
5 ms followed by a 20 ms break. The treatment time was 6 min. 
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3.4. Polarization Microscopic Examinations 
The structures of the samples were examined with a polarization microscope (LEICA Q500 MC 
Image Analyzer System, Leica Microsystems GmbH, Wetzlar, Germany) at room temperature. The 
magnification was 20×. 
3.5. Rheological Investigations 
The rheological profiles of the samples were studied with a PaarPhysica MCR101 rheometer  
(Anton Paar GmbH, Graz, Austria). The measuring device was of plate-plate type (diameter 25 mm, gap 
distance 0.2 mm). The measurements were carried out at 25 °C. The linear viscoelastic range was 
determined in the first step by examining the complex modulus as a function of the shear stress at a given 
frequency (1 Hz). On the basis of these experiments, the shear stress was set at 1 Pa during the dynamic 
testing as this value was always within the linear viscoelastic range. The storage and loss moduli values 
were examined as a function of frequency (0.01–10 Hz). 
3.6. Animal Studies 
Animal studies were conducted on 7–8 week old C57BL/6J female mice with an average weight  
of 20–25 g, purchased from Charles River (Sulzfeld, Germany). The working protocol strictly followed 
all the National Institute of Animal Health (NIAH) regulations: animals were maintained under  
standard conditions throughout the experiments: a 12 h light-dark cycle, food and water ad libitum,  
temperature 24 °C and humidity >55%. The experiments were conducted in accordance with the rules 
of the Ethical Committee of University of Medicine and Pharmacy “Victor Babes” Timisoara, Romania  
no. 27.11.2014_ref.1.2015. The number of mice involved in the study was 30, divided equally into  
6 groups of 5 animals as follows: 
Group A: blank group; 
Group B: mice inoculated with B164A5 cells and otherwise not treated; 
Group C: mice inoculated with B164A5 cells and treated with LLCs without Gen; 
Group D: mice inoculated with B164A5 cells and treated with LLCs with 3% Gen; 
Group E: mice inoculated with B164A5 cells and treated with LLCs without Gen and electroporated 
at high-voltage for 6 min with a Mezoforte Duo Mez 120905-D; 
Group F: mice inoculated with B164A5 cells and treated with LLCs with 3% Gen and electroporated 
at high-voltage for 6 min with a Mezoforte Duo Mez 120905-D. 
On day 0 of the experiment, the mice in groups B–F received a subcutaneous (s.c.) inoculation of  
0.1 mL containing 1 × 106 cells/mouse into the depilated lateral abdomen. For the mice in groups C–F 
treatment with 2 mL of a 3% Gen-LLC formulation was administered from day 2 post-inoculation, using 
6 min of high-voltage electroporation (Mezoforte Duo Mez 120905-D) or the classical application as 
described above. The mice were inspected daily for the development of tumors or other changes. Tumor 
growth was measured daily in millimeters, using calipers, and the tumor volume was estimated by the 
formula: length × width2/2. On day 21 post-inoculation, after the last measurements had been made, the 
mice were anesthetized with gaseous isoflurane. Blood was collected from the cava vein, and the 
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concentrations of the melanoma-specific markers S100B and NSE (neuron specific enolase) were 
investigated. The mice were subsequently euthanized by cervical dislocation. Tumors were collected, 
measured and weighed, and histological and immunohistochemical analyses were performed. 
3.7. Noninvasive Skin Measurements 
All the measurements on the skin of the mice were carried out with a Multiprobe Adapter System 
(MPA5) from Courage-Khazaka, Köln, Germany: the measurements of pigmentation and erythema  
with the Mexameter® MX 18 from Courage-Khazaka, Köln, Germany furnish quantitative information 
relating to the relative melanin pigmentation and erythema (hemoglobin) subject to modifications by 
tumor evolution with or without treatment. 
The measurements were made on four regions of the skin located near the tumor, and the mean and 
standard deviation were calculated. The amounts of melanin and erythema were measured at the  
baseline (day 0) and then every two days until day 21 of the experiment. The measurement areas were  
5 mm in diameter. 
3.8. Determination of Neuron Specific Enolase (NSE) and S100 Calcium Binding Protein B (S100B)  
in the Blood 
The mice were anesthetized with isoflurane, and blood was collected from the posterior vena cava 
and by cardiac puncture and inserted into a serum separator tub. Samples were allowed to clot overnight 
at 4 °C before centrifugation at approximately 1000× g for 20 min. The enzyme-linked immunosorbent 
assay kits for S100 calcium binding protein B (S100B) and neuron specific enolase (NSE) were from 
Cloud Clone Corp. (Houston, TX, USA). The manufacturer’s protocol was used to determine the S100B 
and NSE concentrations in the mouse serum. All kit components and samples were brought to room 
temperature (18–25 °C) before use. 
3.9. Histology 
For histological analysis, tissue samples (skin) were fixed in 4% buffered formaldehyde solution  
and embedded into paraffin. For standardized evaluation, each sample was organized into a tissue 
microarray (TMA) block. Sections of 4 um from the TMA blocks were deparaffinized, stained with 
hematoxylin-eosin (HE) by a Leica Autostainer, Medist, Bucharest, Romania and analyzed 
microscopically. Samples were visualized and archived by computerized scanning microscopy (3D 
Histech Ltd., Budapest, Hungary). 
3.10. Immunohistochemistry 
Sections of 4 µm from the TMA blocks were used for immunohistochemistry. Rabbit antibody of 
PDGFRβ (polyclonal; Sigma-Aldrich Co., St. Louis, MI, USA) was applied in a dilution of 1:2000. 
Antigen retrieval was performed according to the datasheets of the antibody. Visualization was carried 
out with an autostainer with the Leica Bond kit. Sections were counterstained with conventional 
hematoxylin and gently coverslipped. Evaluation was based on the brown colorimetric discoloration of the 
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samples. For intensity assessment, optical densitometry was performed with Image Pro Plus software, 
Media Cybernetics, Rockville, MD, USA. 
3.11. Statistics 
Results are presented as means ± SD. One-way ANOVA followed by the Bonferroni test was  
used to determine the statistical differences between the various experimental and control groups;  
*, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001. “ns” indicates not-significant. 
4. Conclusions 
We conclude that LLCs serve as a good formulation for the local delivery of genistein. Further studies 
will be conducted with higher concentrations of this active agent. Electroporation proved to be a good 
method for the delivery of the new formulation because it delayed the appearance of the tumors, and 
decreased the tumor volume, the amount of melanin and the degree of erythema. HE staining confirmed 
the above events, but this approach did not have a significant effect in terms of the serum concentrations 
of S100B and NSE, or the tissue expression of the PDGFRβ antibody. 
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New Approach of Sucrose Myristate
as a Promising Penetration Enhancer
in Dermal Preparations
The aim of this work was to compare the penetration enhancer
effect of newly developed sucrose myristate with the generally
used sucrose laurate. Hydrogel formulations containing sucrose
esters (SEs) were prepared and the model drug was Ibuprofen
(IBU), which has oral side effects, so applying it in a transdermal
system could be useful. We evaluated the effect of SE hydrogel
formulations on the skin by the noninvasive in vivo test and ex-
amined their concentration dependent influence on the pene-
tration of IBU through synthetic membrane (in vitro) by the
Franz cell method. The results indicated that sucrose myristate
incorporated into hydrogel moistures the skin well and lastingly
and showed a better drug penetration enhancing effect at a
much lower concentration compared to sucrose laurate. Our re-
sults revealed that sucrose myristate could be a promising and
effective penetration enhancer in the pharmaceutical field.
Key words: Sucrose esters, penetration enhancers, dermal do-
sage form, skin hydration, in vitro drug diffusion
Saccharosemyristinsäureester als ein vielversprechender
Penetrationsverstärker in dermalen Zubereitungen – Ein
neuer Ansatz. Ziel dieser Arbeit ist, den penetrationsverstärken-
den Effekt eines kürzlich entwickelten Saccharosemyristinsäu-
reesters mit dem des üblicherweise eingesetzten Saccharoselau-
rinsäuresters zu vergleichen. Hydrogelfomulierungen mit den
Saccharoseestern (ESs) wurden präpariert. Ibuprofen (IBU) wur-
de als Modellwirkstoff eingesetzt. Wegen seiner oralen Neben-
wirkungen könnte sein Einsatz in transdermalen Systemen sinn-
voll sein. Wir bestimmten den Einfluss von SE-haltigen
Hydrogelen auf die Haut mittels nichtinvasiven in-vivo-Tests und
untersuchten ihren konzentrationsabhängigen Einfluss auf die
Penetration von IBU durch eine synthetische Membrane mittels
der Franz-Zellen-Methode. Die Ergebnisse zeigten, dass der in
die Hydrogele befindliche Saccharosemyristinsäureester die Haut
gut und langanhaltend befeuchtet und eine bessere Wirkstoff-
penetration bei sehr geringerer Konzentration im Vergleich zum
Saccharoselaurinsäurester hat. Unsere Resultate machten deut-
lich, dass der Saccharosemyristinsäureester ein vielversprechen-
der und effektiver Penetrationsverstärker auf dem pharmazeuti-
schen Gebiet sein kann.
Stichwörter: Saccharoseester, Penetrationsverstärker, dermale
Verabreichungsform, Hautfeuchtigkeit, in-vitro-Wirkstoffdiffusion
1 Introduction
Sucrose esters (SEs) are non-ionic surfactants consisting of a
sugar substituent, sucrose as the hydrophilic group and fatty
acid as the lipophilic group [1]. These natural compounds
show many advantages such as excellent biodegradability,
biocompatibility and no toxicity [2, 3]. Furthermore, their
HLB value ranges from 1 to 16 [4]. SEs are widely used in
the food and cosmetic industries and they have recently re-
ceived increased attention in the pharmaceutical field [5].
As penetration enhancers, SEs belong to a new generation
of surfactants as promising agents in transdermal therapeu-
tic systems (TTS) to control drug release and enhance pene-
tration [6]. Generally, ionic surfactants are more potent en-
hancers than their non-ionic counterparts, but these agents
can damage the barrier of the skin. SEs cause less dermato-
logical damage while they act by altering the ordered struc-
ture of the intercellular region of the stratum corneum (SC).
The drug release effect of SEs depends on their HLB value
and the C atom number of the fatty acid chain [7]. The most
potent SEs enhancers are with shorter fatty acid chain
length and higher HLB value [7, 8]. In the case of TTS patch
formulation, sucrose laurate (C = 12, HLB = 16) was found
to be the best penetration enhancer [7]. However, the enhan-
cing efficacy of a surfactant is dependent not only on its
structure, but also on the physicochemical properties of the
drug, and the nature of the vehicle may also play an impor-
tant role in the surfactant–skin interaction [9].
Sucrose myristate is a monoester of myristic acid and su-
crose. It has many applications in the cosmetics and perso-
nal care industry as surfactant, emulsifying, skin-condition-
ing agent and emollient [10]. It has food and cosmetic grade
with a HLB value of 16 and a linear alkyl chain of 14 carbon
atoms. These structural parameters make sucrose myristate
an attractive candidate to serve as a possible absorption en-
hancer in dermal drug delivery systems.
In this study we prepared hydrogel formulations contain-
ing SEs. The penetration of a drug into the deeper layers can
be enhanced through a well-hydrated skin, too. During
moisturizing, the intercellular space between the corneo-
cytes increases due to the swelling of SC. Furthermore, in
many dermatological disorders a significant improvement
can be achieved with a well-moisturizing vehicle even in
the absence of any active compounds [11]. Our model drug
was Ibuprofen – used for the treatment of musculoskeletal
disorders – because the transdermal delivery of non-steroi-
dal anti-inflammatory drugs (NSAIDs) offers several advan-
tages over the conventional dosage forms.
The primary aim of this work was to investigate the effect
of two SEs (sucrose laurate and sucrose myristate) in human
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skin in vivo and to evaluate their concentration dependent
enhancing effect on the in vitro drug liberation of Ibuprofen
from hydrogel based topical formulation.
2 Materials and Methods
2.1 Materials
Sucrose laurate (D-1216) and sucrose myristate (C-1416)
were a generous gift from Mitsubishi-Kagaku Foods Cor-
poration (Tokyo, Japan). Ibuprofen (IBU) was purchased
from Sigma-Aldrich (St Louis, United States). Carbopol
971P was supplied by Lubrizol Corporation/Azelis (Buda-
pest, Hungary). Polyethylene glycol 400 (PEG 400) and Tro-
lamine was from Hungaropharma Ltd (Budapest, Hungary).
2.2 Sample preparations
API free hydrogel (Blank gel) was prepared by the following
procedure. PEG 400 (20 wt.%) solution was added to Carbo-
pol 971P hydrogel. The pH value was adjusted by adding
Trolamine (7 wt.%). A penetration enhancer free IBU gel
was prepared by the same method, 5 wt.% IBU was dis-
solved in PEG 400. In order to compare the effect of differ-
ent SEs, we formulated 2.64 wt.% SE containing compo-
sitions using sucrose laurate (IBU-D1216 2.64 wt.% gel)
or sucrose myristate (IBU-C1416 2.64 wt.% gel). The
2.64 wt.% was chosen because this was the maximum SE
concentration containing hydrogel which did not require
centrifugation process to remove the bubbles. Different SE
concentration gels were also prepared by a similar method
(IBU-D1216 1; 2; 4; 6; 8,; 10 wt.% gel, IBU-C1416 0.25; 0.5;
1; 2; 4; 6; 10 wt.% gel) to investigate the in vitro diffusion in-
fluenced by the penetration enhancer contents.
2.3 Skin hydration measurements
Skin hydration was measured by Corneometer= CM 825
(Courage and Khazaka Electronic GmbH, Cologne, Ger-
many). Seven healthy female volunteers of ages between 23
and 60 years with no history of dermatological diseases or
allergy participated in the experiment (approved by the local
ethics committee: Regional and Institutional Human Medi-
cal Biological Research Ethics Committee at the University
of Szeged) after giving their written consent. All volunteers
were asked not to apply any moisturizer or cosmetic product
for at least 24 h before the process. Measurements were per-
formed under standardized conditions (room temperature
of 21–23 8C, and 40–50% RH). Time was allowed for the
patients to adapt to room conditions. 0.3 g of the samples
(Blank gel and API free 2.64 wt.% SE containing formula-
tions) was applied on the dorsal hand (3 · 3 cm area) of all
the subjects. The electrical capacitance of the SC, indicating
the hydration level of the SC was determined before and
after the sample application at 30, 90 and 150 min. The
measured values were compared with the values detected
on the non-treated skin. The changes in moisturizing level
were expressed in percentage [12–14].
2.4 Drug diffusion investigations
Membrane diffusion studies were carried out with vertical
Franz-diffusion cell system (Hanson Research, Chatsworth,
CA, USA). The surface area for diffusion was 1.767 cm2. A
stirring rate of 450 rpm was used. The donor phase was
0.30 g of sample, which was placed on cellulose acetate
membranes (Porafil, Machenerey-Nagel, Germany and Pall
Life Sciences, USA) itself (in vitro). PBS (pH = 7.4) was used
as an acceptor phase [15]. The receptor medium tempera-
ture was maintained at 37 € 0.5 8C throughout the experi-
ments to strengthen the physiological skin temperature
(32 € 0.5 8C) on the membrane in the Franz cell [16–18].
The experiments were performed for 24 h [19]. Samples of
0.8 mL were taken from the acceptor phase by the autosam-
pler (Hanson Research, Chatsworth, CA, USA) and replaced
with fresh receiving medium. The absorbance of the IBU
content was measured by UV spectrophotometer (Unicam
Hekios a Thermospectronic UV-spectrophotometer v4.55,
UK) at a wavelength of k = 263 nm [20]. Five parallel mea-
surements were done with plotting the penetration amount
of IBU over a time period. Results were expressed as the
mean € SD.
2.5 Dissolution analysis
Permeation parameters were obtained from the cumulative
amount of IBU permeated per cm2 versus time plots (Q).
The steady state flux (J) was obtained from the slope of the
linear regression versus t1/2, respectively. The permeability
coefficient (Kp) was calculated according to Fick’s first law
of diffusion, based on the steady state flux and the applied
drug concentration (Cd) of the donor phase [21]:
Kp ¼ J=Cd ð1Þ
The effectiveness of penetration enhancers was determined
by comparing the Kp in the presence and absence of the en-
hancer. This was defined as the enhancer index (EI), which
was calculated using the Kp of the hydrogels with enhancer
(Kpe) and the Kp of the enhancer free IBU-gel (Kpef) [19]:
EI ¼ Kpe=Kpef ð2Þ
2.6 Statistical analysis
Two-way ANOVA was performed to see any significant dif-
ference in the diffused and permeated amount of IBU (Q)
between the control (IBU gel) and test preparations using
GraphPad Prism software (Graph-Pad Software Inc., CA,
USA). Differences were regarded as significant with p <
0.05*, p < 0.01*, p < 0.001***.
3 Results and Discussion
3.1 In vivo skin test
As discussed earlier, increased tissue hydration appears to
increase skin penetration. This is the most widely used and
safest method to increase the transdermal delivery of both
hydrophilic and lipophilic compounds. The ideal semisolid
dermal drug delivery system should moisture the skin well
to enhance the drug penetration.
Figure 1 shows that every sample increased the hydrated
state of the skin and ensured a good, lasting moisturizing
effect. The greatest increase in skin water content was ob-
tained with 2.64 wt.% sucrose myristate gel, exhibiting a 3-
fold increase after 30 min, 1.6-fold increase after 90 min
and 1.3-fold increase after 150 min. The application of the
2.64 wt.% sucrose myristate gel results in significantly high-
er skin hydration compared to the Blank gel after 30, 90 and
150 min (p < 0.001***). The Blank gel and the 2.64 wt.% su-
crose laurate gel showed a similar hydration state after
30 min, but after 90 min the 2.64 wt.% sucrose laurate gel
achieved a greater and more enduring moisturizing effect
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than the Blank gel. However, the results were not statisti-
cally significant compared to the SE free hydrogel.
It was proved earlier that sucrose laurate acts as an effec-
tive and non-irritating hydration and penetration enhancer
for IBU through the skin [6]. Based on our results, it can
be concluded that the SEs incorporated into the hydrogel ve-
hicle interact synergistically to modify the skin barrier, but
statistically sucrose myristate achieved a higher skin water-
holding capacity increase. The SEs have the same HLB value
(HLB = 16), but using the 14 C-atom-long fatty acid chains,
sucrose myristate in a hydrogel formulation is probably able
to integrate into the SC lipid bilayer more efficiently than
sucrose laurate (C = 12).
3.2 In vitro drug release
First, in order to investigate how the SEs influenced the diffu-
sion of IBU in vitro, we tested the 2.64 wt.% SE content for-
mulations. Figure 2. presents the cumulative amount per unit
area of IBU diffused through synthetic membrane from the
different formulations against time. Without penetration en-
hancers, the drug liberation was about 6687.58 € 823.86 in
24 h. Both 2.64 wt.% SE containing hydrogels increased IBU
diffusion, but in this concentration great differences were not
observed between the different SEs. Although sucrose laurate
containing hydrogel caused slightly slower drug release than
the IBU gel in the first hours, the cumulative drug amount in
24 h was greater than in case of the IBU gel. The diffused
drug amounts were not statistically significant in this case.
However, using sucrose myristate, the amount of the liber-
ated drug was similar to the IBU gel in the first 3 h, but after
the 9th hour the difference between the IBU amount diffused
from IBU gel and IBU-C1416 2.64 wt.% gel was statistically
significant (p < 0.05*).
After this, to examine the effect of penetration enhancer
concentrations on in vitro drug diffusion, we carried out in
vitro tests with both SE gels in different concentrations.
The steady state fluxes (J) – representing the absorption rate
per unit area – and the enhancer indexes (EI) suggest that
sucrose laurate has a concentration dependent enhancing ef-
fect (Table 1). It can be seen that from 2 wt.% sucrose lau-
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Figure 1 Skin water hydration measurement after single application of three
Ibuprofen free topical formulations: penetration enhancer free hydrogel
(Blank gel), 2.64% sucrose laurate gel (D1216 2.64% gel) and 2.64%
sucrose myristate gel (C1416 2.64% gel) given as average values ± SD over
all 7 volunteers. The differences between Blank gel and C1416 2.64% gel for
each test measurement time are significant using two-way ANOVA
(p < 0.001***)
Figure 2 The cumulative diffused amount of
Ibuprofen through synthetic membrane given as
average values ± SD (n = 5 for each formula-
tion). Diffused amounts are compared to pene-
tration enhancer free IBU gel and with 2.64%
sucrose laurate gel (IBU-D1216 2.64% gel) as
well as with a 2.64% sucrose myristate gel
(IBU-C1416 2.64% gel)
Formulation Q (lg cm–2) J (lg cm–2 h–1) Kp · 10–3 (cm h–1) Enhancer Index (E1)
IBU-gel 6687.59 ± 869.12 971.73 19.43 1.00
IBU D1216 1% gel 2443.09 ± 452.22 117.05 2.34 0.12
IBU D1216 2% gel 7002.61 ± 1674.47 1248.60 24.97 1.28
IBU D1216 2.64% gel 8213.55 ± 1092.08 1629.60 32.59 1.68
IBU D1216 4% gel 8331.24 ± 478.75 1619.40 32.39 1.67
IBU D1216 6% gel 10824.16 ± 1130.68 2282.30 45.65 2.35
IBU D1216 8% gel 10317.58 ± 1736.76 2233.70 44.67 2.29
IBU D1216 10% gel 7542.37 ± 930.57 1575.60 31.51 1.62
Table 1 Diffusion parameters of Ibuprofen from different sucrose laurate containing hydrogels after 24 h (J: steady state flux; Kp: permeability coefficient)
rate content the EI values and the diffused amount of IBU
after 24 hour were better than in case of the penetration en-
hancer free hydrogel. We got a maximum curve and the best
penetration of IBU was strengthened by the 6 wt.% sucrose
laurate gel (Fig. 3.). This gel showed the highest IBU diffu-
sion profile and after the 10th hour the results were signifi-
cant. Then 8 wt.% and 10 wt.% sucrose laurate containing
hydrogels showed lower penetration parameters than
6 wt.% sucrose laurate gel.
When examining sucrose myristate, the same tendency
was observed, we found a maximum curve again, but this
curve reached the maximum at much lower SE concentra-
tion. The diffusion profile of IBU from the 0.5% sucrose
myristate containing gel was the highest and after the 3rd
hour this formulation showed the earliest significantly in-
creased diffused IBU amount (p < 0.05*) compared to the
IBU gel (Fig. 4.). This gel reached the best IBU diffusion
profile and enhanced the IBU diffusion 1.5 fold when com-
paring the EI value of 6% sucrose laurate gel. Based on the
enhancer indexes it could be established, too, that sucrose
myristate up to 4% is a more effective diffusion increaser
for IBU than sucrose laurate through synthetic membrane
(Table 2).
4 Conclusion
Our results indicate that sucrose myristate is a promising
agent in hydrogel formulation for Ibuprofen to enhance the
penetration. The in vivo results demonstrated that the incor-
poration of sucrose esters – especially sucrose myristate –
into hydrogel extends and increases the hydration phenom-
enon. Sucrose myristate significantly improved the moistur-
izing effect of blank hydrogel vehicle. Furthermore, it could
be established that the sucrose ester concentration influ-
enced the in vitro absorption process notably. It could be
concluded from our study that both tested SEs have a con-
centration dependent enhancing effect and it is not worth
using the tested SEs above a certain concentration. While
sucrose laurate is an effective penetration enhancer in 6%
concentration, sucrose myristate presented a better enhan-
cing effect at a much lower concentration. In case of sucrose
myristate, this effect maximized at 0.5%. On the one hand,
this phenomenon has not negligible economic aspects, and
the other hand, it also facilitates hydrogel preparation. These
results suggest that food and cosmetic grade sucrose myris-
tate will be useful as a penetration enhancer in the pharma-
ceutical field. Furthermore, our results present that it is al-
ways important to determine the minimum and maximum
effective concentration of the penetration enhancer because
it could be influenced by the physicochemical properties of
the drug and the vehicle, too.
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Figure 3 The diffused amount of Ibuprofen from different sucrose laurate
containing hydrogels after 24 h (average value ± SD, n = 5)
Figure 4 The diffused amount of Ibuprofen from different sucrose myristate
containing hydrogels after 24 h (average value ± SD, n = 5)
Formulation Q (lg cm–2) J (lg cm–2 h–1) Kp · 10–3 (cm h–1) Enhancer Index (E1)
IBU-gel 6687.59 ± 869.12 971.73 19.43 1.00
IBU C1416 0.25% gel 11075.59 ± 1251.89 2166.20 43.32 2.76
IBU C1416 0.5% gel 14166.39 ± 549.12 2792.30 55.85 3.56
IBU C1416 1% gel 11753.84 ± 1152.88 2192.80 43.86 2.79
IBU C1416 2% gel 10449.58 ± 766.22 2109.20 42.18 2.69
IBU C1416 2.64% gel 9999.87 ± 1581.83 1932.80 38.66 2.46
IBU C1416 4% gel 9675.14 ± 1784.70 1927.90 38.56 2.46
IBU C1416 6% gel 7198.69 ± 1070.05 1387.00 27.54 1.77
IBU C1416 10% gel 1619.33 ± 282.15 312.24 6.24 0.39
Table 2 Diffusion parameters of Ibuprofen from different sucrose myristate containing hydrogels after 24 h (J: steady state flux; Kp: permeability coefficient)
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Abstract: The aim of the present work was the optimization of the 
transdermal delivery of a lyotropic liquid crystal genistein-based 
formulation (LLC-GEN). LLC was chosen as medium in view of the poor 
solubility of GEN in water. Membrane diffusion and penetration studies 
were carried out with a Franz diffusion cell, through a synthetic membrane 
in vitro, a chick chorioallantoic membrane ex ovo, and ex vivo excised 
human epidermis. Thereafter, LLC-GEN was combined with 
electroporation (EP) to enhance the transdermal drug delivery. The 
synergistic effect of EP was verified by in vivo ATR-FTIR and ex vivo 
Raman spectroscopy on hairless mouse skin. 
©2015 Optical Society of America 
OCIS codes: (170.3880) Medical and biological imaging; (300.6540) Spectroscopy, ultraviolet; 
(120.7280) Vibration analysis; (300.6340) Spectroscopy, infrared; (300.6300) Spectroscopy, 
Fourier transforms; (170.5660) Raman spectroscopy. 
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1. Introduction 
The transport of molecules through the skin is made difficult by the presence of the stratum 
corneum (SC). The epidermis is an intricate and highly inhomogeneous structure built up 
from different layers, but the SC (the outermost layer of the skin consisting of dead flattened 
cells) causes its barrier function, such as the electrical properties [1, 2]. Transdermal drug 
delivery has a number of advantages over conventional delivery methods such as oral 
administration and injection (e.g. elimination of the first-pass metabolism, the minimization 
#253195 Received 2 Nov 2015; revised 18 Nov 2015; accepted 18 Nov 2015; published 8 Dec 2015 
(C) 2015 OSA 1 Jan 2016 | Vol. 7, No. 1 | DOI:10.1364/BOE.7.000067 | BIOMEDICAL OPTICS EXPRESS 68 
of pain, and the possibility of the sustained release of drugs). However, for the delivery of 
large molecules through the skin, the use of chemical or physical methods is unavoidable [1]. 
Electroporation (EP) involves the application of short (microsecond to millisecond) pulses 
of high voltage (HV) to achieve a transitory structural perturbation of the lipid bilayer 
membranes. Its main advantages are that it is easy and rapid, and is able to open different 
kinds of lipid bilayer membranes: artificial (liposomes), cellular (bacterial, yeast, plant and 
mammalian cells) or even more complex structures (e.g. SC) [3]. Through the use of skin EP, 
the transdermal delivery of small dyes, drugs, oligonucleotides, DNA plasmids, antigens, 
hydrophilic molecules, neutral or highly charged compounds, and macromolecules with 
molecular weights up to 40 kDa can be enhanced by several orders of magnitude [4, 5]. 
Currently the most broadly developing area of EP is electrochemotherapy, which is an 
effective way to treat cutaneous and subcutaneous tumours: HV pulses are applied to 
permeabilize tumour cells to an impermeable cytotoxic drug, which is administered by 
injection either into a vein or directly into a tumour [6]. 
Genistein (GEN; 4,5,7-trihydroxyisoflavone), one of the most abundant isoflavones in 
soybeans, is also called a phytoestrogen because of its structural similarity to the human 
hormone 17β-oestradiol [7]. GEN, a potent tyrosine kinase inhibitor, has been extensively 
used in the prevention and treatment of many diseases and disorders, including cancer, 
cardiovascular diseases, osteoporosis and postmenopausal symptoms [8]. Danciu et al. 
demonstrated the beneficial effects of GEN as regards tumour size, metastasis potential and 
melanization in a B16 mouse model of murine melanoma [9]. However, GEN is only poorly 
soluble in water and this can be a serious problem in terms of formulation [10]. 
A topically applied GEN-based lyotropic liquid crystal (LLC) formulation was earlier 
developed and combined with EP to treat murine melanoma lesions [11, 12]. The results 
showed that this strategy is promising for the recovery of skin lesions of murine melanoma 
type. LLCs are novel nanosystems usually formed from water and one or two surfactants, 
possibly with cosurfactants and oils. The main advantages of these systems include their 
similarity with colloidal systems existing in living organisms, their thermodynamic stability, 
and the situations that they can be stored for long periods of time without phase separation, 
they exhibit good penetration and they can facilitate the progressive diffusion of biologically 
active substances into the skin or systemic circulation. Besides their good solubilizing effects, 
they are able to incorporate and control the release of drugs of varying size and polar 
characteristics as they contain lipophilic, hydrophilic and amphiphilic domains [13, 14]. 
In the present work, the diffusion and penetration of GEN and LLC-GEN through 
different membranes were first investigated by conventional treatment without EP, and also 
with the mediation of EP. Measurements were made with a Franz diffusion cell system 
through a synthetic membrane in vitro, chick chorioallantoic membrane (CAM) ex ovo and 
excised human epidermis ex vivo. CAM has been introduced as a new and useful biological 
membrane model for preclinical permeability studies of pharmaceutical substances [15]. 
Vibrational spectroscopies were used to investigate the effects of EP on animal skin. 
Infrared (IR) and Raman spectroscopy have recently received increased attention in both the 
cosmetic and pharmaceutical fields. These methods offer attractive possibilities for the study 
of EP-mediated drug delivery. 
Attenuated total reflection Fourier transform IR spectroscopy (ATR-FTIR) is a suitable 
tool with which to study the structure of the SC at the molecular level, to characterize its 
lipids, proteins and water content [16], and to analyse the penetration of drugs into the skin 
and the biochemical modifications induced by the penetration [17]. ATR-FTIR is essentially a 
non-destructive sampling technique which combined with tape-stripping serves as a rapid, 
simple, non-invasive method for studies of the skin. Through sequential tape-stripping, SC 
layers can be obtained from the deeper regions. The ATR device allows a spectrum to be 
acquired from a surface of a sample without preparation [18]. FTIR spectrometric studies on 
GEN have been investigated and reported earlier [19]. 
Raman spectroscopy is also widely used to study biological samples and to study the skin 
[20]. It has been utilized to determine the structures of GEN-cyclodextrin inclusion complexes 
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[21], GEN and other 5-hydroxyisoflavones [22]. The assignment of the Raman spectrum of 
native skin was reported by Pouliot [23]. Confocal Raman images have been investigated as 
chemical maps of ex vivo pigskin [24] and ex vivo human abdominal skin [25]. 
Following an investigation of the transdermal delivery of our newly developed LLC-GEN 
formulation through different membranes without EP, LLC-GEN was combined with EP to 
examine the efficiency of this combination by means of in vivo ATR-FTIR and ex vivo Raman 
spectroscopy. With vibrational spectroscopic monitoring, various treatment times and 
voltages were applied to evaluate the effects of EP on the skin. 
2. Materials and methods 
2.1. Materials 
GEN was purchased from Extrasynthèse (Genay, France; purity >95%), and the non-ionic 
surfactant Cremophor RH 40 (CRH40; Polyoxyl 40 Hydrogenated Castor Oil USP/NF) from 
BASF (Ludwigshafen, Germany). The aqueous phase of the systems was purified water 
(Ph.Eur.6.), and the oil phase was isopropyl myristate (IPM; Merck Kft., Budapest, Hungary). 
The average particle size of GEN is 12.04 ± 7.74 µm (n = 564). 
2.2. Sample preparation 
Samples produced with a 2:1 by the oil-surfactant mixture were homogenized with a magnetic 
stirrer at room temperature, and 10 wt.% of water was then added in small amounts under 
stirring. For the drug-containing samples, 3 wt.% of GEN as active agent was partly dissolved 
(1 wt.%) in the oil-surfactant mixture with the aid of a magnetic stirrer. 
2.3. Drug diffusion and penetration investigations 
2.3.1. Preparation of CAM 
Fertilized chicken eggs (Gallus gallus domesticus) were prepared for the experiment by 
cleaning with ethanol, and then placed horizontally in an incubator at 37 °C, with constant 
humidity. On the third day of incubation, 3–4 mL of albumen was extracted from the most 
pointed part of the egg, so that the developing CAM could be detached from the inner shell in 
order to work directly on the membrane. On day 4 of incubation, a window was cut in the 
surface of the egg, it was resealed with adhesive tape and incubation was continued until the 
day of the experiment. CAMs were collected in buffered formalin and used for ex ovo studies. 
2.3.2. Preparation of heat-separated epidermis 
With the approval of the Ethical Committee of the University of Szeged, Albert Szent-
Györgyi Clinical Centre (Human Investigation Review Board licence number: 83/2008.), 
excised human skin was obtained from a Caucasian female patient who underwent abdominal 
plastic surgery. This was. The subcutaneous fatty tissue was separated from the outer skin 
layers after excision and the skin was stored at −20 °C. For the penetration experiment, after 
the skin had thawed, the epidermis was separated from the underlying dermis by a heat-
separation technique [26]. Individual portions were immersed in water at 60 °C for 90 s. After 
removal of the skin from the water, it was placed SC side up on a filter paper, and the 
epidermis (comprising the SC and the viable epidermis) was gently removed from the 
underlying dermis with the use of forceps and was discarded. The epidermal membrane was 
floated onto the surface of PBS (phosphate buffer solution, pH = 7.4) for at least 20 min and 
then placed on a supporting cellulose acetate membrane (Porafil, Machenerey-Nagel, Düren, 
Germany, and Pall Life Sciences, Washington, NY, USA; pore diameter 0.45 μm) [27, 28]. 
2.3.3. Franz diffusion cell method 
Membrane diffusion and permeability studies of GEN were carried out with a vertical Franz 
diffusion cell system (Hanson Research, Chatsworth, CA, USA) in a six-unit assembly 
(effective permeation area 1.33 cm2) for 24 h (in vitro or ex ovo) or 48 h (human epidermis) at 
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37 °C. The donor phase was 0.30 g of sample, which was placed on a cellulose acetate 
membrane (Porafil, Machenerey-Nagel, Düren, Germany, and Pall Life Sciences, 
Washington, NY, USA) itself (in vitro), or in the case of ex ovo and ex vivo measurements the 
CAM and the epidermis were supported with a Porafil membrane filter. The acceptor 
compartment consisted of 10 wt.% ethanol containing PBS (pH 7.4), which was stirred at 450 
rpm throughout the experiment. Samples of 0.8 mL were taken from the acceptor phase by the 
autosampler (Hanson Research, Chatsworth, CA, USA) and replaced with an equal volume of 
fresh receiving medium. The absorbance of the GEN content was measured at 261 nm with a 
Unicam Heλios α Thermospectronic UV-spectrophotometer v4.55 (Unicam, Thermo Fisher 
Scientific Inc., Waltham, MA, USA). Five parallel measurements were carried out and the 
amount of GEN penetrating during a time period was plotted. The results were expressed as 
means ± SEM. 
2.3.4. Penetration analysis 
Penetration parameters were obtained from the cumulative amount of GEN penetrated per 
cm2 versus time plots (Q). The transdermal flux (J) was calculated from the slope of the 
concentration versus time profile in the receiver compartment, and expressed in µg cm−2 h−1. 
For the linear regression analysis, the linear range of the incubation period from 1 to 6 h was 
selected, and was used to calculate the flux data of the compounds. 
2.4. EP parameters 
A Mezoforte Duo Mez 120905-D instrument (Dr Derm Equipment Ltd., Budapest, Hungary) 
was used to generate the electric pulses for the skin EP. The operation of this device is based 
on a pulsed electromagnetic field generated by an amplitude-modulated sine wave 
radiofrequency current. The polypropylene-covered treatment headpiece contains a plate 
electrode 25 mm in diameter indirectly contact with the treated surface. Modulation involves 
HV pulses 5 ms in duration, followed by a 20 ms break. GEN transport by means of skin EP 
can be influenced by using 700 V or 900 V with different treatment times (1 or 2 min). 
2.5. Animal experiments 
12-week-old male SKH-1 hairless mice were housed in plastic cages in a thermoneutral 
environment with a 12 h light-dark cycle and had access to standard laboratory chow and 
water ad libitum. All interventions were in full accordance with the NIH guidelines and the 
protocols were approved in advance by the Ethical Committee for the Protection of Animals 
in Scientific Research at the University of Szeged (licence number: V./145/2013). Prior to the 
intervention, the animals were anaesthetized with a mixture of ketamine (90 mg (kg 
bodyweight)−1) and xylazine (25 mg (kg bodyweight)−1) administered intraperitoneally. At the 
end of the experiments, the mice were euthanized with an overdose of ketamine (300 mg 
kg−1). 
The mice involved in the study were divided into 5 groups as follows: 
Group A: mice treated with dermally applied LLC-GEN for 2 min 
(conventional treatment) 
Group B: mice treated with LLC-GEN and EP at 700 V for 1 min 
Group C: mice treated with LLC-GEN and EP at 900 V for 1 min 
Group D: mice treated with LLC-GEN and EP at 700 V for 2 min 
Group E: mice treated with LLC-GEN and EP at 900 V for 2 min 
For ATR-FTIR measurements, 5 mice were randomly assigned to each experimental 
condition. Corneocytes were collected from the uppermost layer of their dorsal skin with the 
use of adhesive tape (D Squames, CuDerm Corporation, Dallas, TX, USA) immediately after 
treatment. The treated and the untreated dorsal skin of each mouse was stripped with adhesive 
tape; this procedure was repeated up to 18 strips, an IR spectrum being recorded after every 
third tape strip. Every first tape with one strip was discarded because of the possibility of 
surface contamination. 
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For Raman measurements, 2 mice were randomly assigned to each of groups A, C and E. 
At the end of the observation period of these groups, the animals were sacrificed (as described 
above) and full-thickness skin samples were excised from the treated areas. The samples were 
embedded in Cryomatrix resin (Thermo Fisher Scientific Inc., Waltham, MA, USA) and 
cryosections of 6 μm were made. 
2.6. ATR-FTIR measurements 
ATR-FTIR spectra were recorded with an Avatar 330 FT-IR spectrometer (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) equipped with a horizontal ATR crystal (ZnSe, 45°), 
between 4000 and 400 cm−1, at an optical resolution of 4 cm−1. 128 scans were co-added and 
all spectral manipulations were performed with the Thermo Scientific's GRAMS/AI Suite 
software. In order to obtain a reference spectrum of the API, a KBr pellet containing 0.5 mg 
of GEN was prepared and used. The spectra of the preparations were also recorded. The 
spectra of five parallel samples, gained from five different animals, were recorded. Each 
average layer spectrum of the treated SC was corrected with the corresponding average layer 
spectrum of the untreated SC. No ATR correction was performed. 
2.7. Raman measurements 
Raman spectra were acquired with a Dispersive Raman Microscope (Thermo Fisher Scientific 
Inc., Waltham, MA, USA) equipped with a CCD camera and a diode laser operating at 780 
nm. The spectra of the CRH40, IPM and GEN were collected with an exposure time of 6 s, 
with 48 scanning and cosmic ray and fluorescence corrections. Raman measurements were 
carried out with a laser power of 12 mW at a slit width of 25 µm. The localization of GEN in 
the skin samples was investigated by confocal Raman mapping. For mapping, the microtomed 
skin samples as depth sections were rotated by 90° and placed on an aluminium surface with 
the SC towards the top of the plate. Thus, a 1000 µm length of the sample specimen 
corresponds to a 1000 µm depth into the skin. The mapping was achieved in a point-by-point 
mode, using a step size of 10 µm perpendicular and parallel to the SC. Raman maps of skin 
with dimensions 30-40 µm parallel and 900-1300 µm perpendicular to the SC surface were 
generated one-by-one. The spectrum acquisition time was 3 s per spectrum, and 24 spectra 
were accumulated and averaged at each measured point, these parameters ensuring an 
acceptable signal-to-noise ratio. The mapping was carried out with a laser power of 24 mW at 
a slit width of 25 µm. The vibrational chemical images were studied by a multivariate curve 
resolution – alternating least squares chemometric method; the purpose was to identify GEN 
in the Raman spectra. 
2.8. Statistical analysis 
Two-way ANOVA was used to identify any significant differences in the total penetrated 
amount of GEN between the conventional treatment and the combined EP treatments by using 
GraphPad Prism software (Graph-Pad Software Inc., La Jolla, CA, USA). Differences were 
regarded as significant if p < 0.05* and p < 0.001***. 
3. Results and discussion 
3.1. Drug diffusion and penetration 
The membrane diffusion investigations indicated that good drug release and diffusion was 
attained through the synthetic membrane in vitro, 713.26 ± 90.73 µg cm−2 being liberated in 
24 h (Fig. 1(a)). Somewhat less drug was observed after 24 h (491.26 ± 15.55 µg cm−2) in the 
case of ex ovo penetration (Fig. 1(b)). In the ex vivo investigations which revealed not only 
the amount of drug that diffused through the skin, but also the interaction with the skin and 
the incidental reservoir function of the SC, only a small amount of drug penetrated through 
the human epidermis (8.93 ± 1.81 µg cm−2 after 24 h and 15.68 ± 3.09 µg cm−2 after 48 h), but 
the penetration profile was similar to that for ex ovo penetration and sustained drug release 
was achieved (Fig. 1(c)). The transdermal flux (J) (reflecting the absorption rate per unit area) 
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showed that the drug penetration was slowed down by the application of the biological 
membrane, and that LLC-GEN alone was not sufficient to reach an appropriate plasma 
concentration. 
 
Fig. 1. Amount of GEN diffused in vitro (a), or penetrated ex ovo (b) or ex vivo (c). 
3.2. ATR-FTIR spectroscopy 
The penetration profile of GEN within the different layers of the SC was established with a 
combination of tape stripping and ATR-FTIR spectroscopy. The most characteristic peaks in 
the ATR-FTIR spectrum of GEN were assigned to the C1 = C2 stretch at 1652 cm−1, and the 
C = O stretch, O7-H22 bend, and ring A C-C stretch at 1518 cm−1 (Fig. 2) [19]. 
Table 1 presents the relative absorbances in the SC layers at 1652 cm−1 and 1518 cm−1, 
which correspond to the amounts of GEN that penetrated into the SC after conventional and 
EP treatments (Fig. 3). The drug delivery and the onset time for transport depend on the 
electrical parameters of the pulses and the physicochemical properties of the drug [3]. It was 
found that EP treatment at 700 V for 1 min EP treatment did not enhance the GEN 
transdermal delivery relative to the conventional treatment. This may be explained by the high 
viscosity of the drug carrier, which decreases the efficacy of EP on the skin [29]. Slightly 
deeper GEN penetration was ensured by EP treatment at 900 V for 1 min, but the total amount 
of GEN did not exceed that for conventional treatment with LLC-GEN. However, EP 
treatment at 700 V for 2 min resulted in a deeper penetration of a 2-fold amount of the drug 
than without EP treatment (revealed at both characteristic bonds of GEN). The best 
penetration profile of GEN was obtained on EP treatment at 900 V for 2 min, when the total 
amount of the drug was 3-fold greater as compared with conventional treatment at both 
assigned bonds (p < 0.001*** and p < 0.05*), but the GEN distribution was not consistent. 
The presence of GEN was not seen in the 5th and 6th tape strips, whereas the drug appeared 
again in the 7th strips. This phenomenon could be explained by the electrical breakdown of 
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the SC layers. Furthermore the amount of drug that penetrated increased with increasing 
voltage of the pulses [30, 31]. 
 
Fig. 2. ATR-FTIR spectra of pure GEN (a), Cremophor RH 40 (b), isopropyl myristate (c), 
LLC-GEN composition (d) and non-treated SC (e). 
Table 1. Intensities of GEN in the different layers of the treated SC (average value ± SD, 
n = 3) (CT = conventional treatment). 
Treated with 
LLC-GEN (CT, 
2 min) 
Treated with 
LLC-GEN + EP 
(700 V, 1 min) 
Treated with 
LLC-GEN + EP 
(900 V, 1 min) 
Treated with 
LLC-GEN + EP 
(700 V, 2 min) 
Treated with 
LLC-GEN + EP 
(900 V, 2 min) 
No. 
of 
tape 
strips 
Absorbance at Absorbance at Absorbance at Absorbance at Absorbance at 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1 
0.06 ± 
0.03 
0.05 ± 
0.02 
0.05 ± 
0.05 
0.04 ± 
0.04 
0.04 ± 
0.01 
0.03 ± 
0.00 
0.15 ± 
0.02 
0.12 ± 
0.02 
0.22 ± 
0.10 
0.18 ± 
0.08 
2 
0.03 ± 
0.01 
0.03 ± 
0.01 
0.02 ± 
0.02 
0.02 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.04 ± 
0.02 
0.04 ± 
0.02 
0.08 ± 
0.06 
0.07 ± 
0.05 
3 
0.03 ± 
0.02 
0.02 ± 
0.01 - - 
0.03 ± 
0.00 
0,03 ± 
0.00 
0.06 ± 
0.00 
0.05 ± 
0.00 
0.06 ± 
0.00 
0.05 ± 
0.00 
4 - - - - 
0.03 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.03 ± 
0.01 
0.03 ± 
0.01 
5 - - - - - - 
0.01 ± 
0.00 
0.01 ± 
0.00 - - 
6 - - - - - - - - - - 
7 - - - - - - - - 
0.02 ± 
0.02 
0.02 ± 
0.01 
8 - - - - - - - - - - 
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 Fig. 3. Total intensities of GEN at 1652 cm−1 and at 1518 cm−1. Conventional treatment (CT) 
was used as a control. p < 0.001*** and p < 0.05* vs. EP-treated group. 
3.2. Raman spectroscopy 
The deeper skin penetration of LLC-GEN containing the lipophilic ingredients CRH40 and 
IPM was studied in Raman scattering experiments. Raman chemical mapping was employed 
to confirm the localization of GEN at various depths of the skin specimens. Since ATR-FTIR 
demonstrated that EP treatment at 900 V ensured deeper penetration than that at 700 V, EP 
treatments at 900 V for 1 and 2 min were chosen for comparison with conventional treatment 
by Raman spectroscopy. 
Figure 4 depicts the experimental Raman spectra of pure CRH40, IPM and GEN in the 
wavenumber range 2000-200 cm−1. As model solution, GEN was dissolved in CRH40 and 
IPM containing LLC (GEN content 3 wt.%) to observe the physical state of GEN. Six 
common characteristic ranges can be seen in the spectra of CRH40 and IPM, with peaks 
centred at 1733, ∼1442-1437, 1300, 1063 and 843-823 cm−1, and the spectra of CRH40, IPM 
and the LLC-GEN composition are very similar. Table 2 lists the Raman bands of the 
components and the LLC-GEN composition. The lipid components used in this study have 
similar chemical structures and therefore similar Raman bands. The Raman spectrum of the 
LLC-GEN is basically the sum of the individual spectra, with minor shifts at around 1440 and 
1079 cm−1 (Fig. 4(c)), indicating that the CH2-CH3 bonds of the LLC ingredients were 
affected by the interaction. Only a few Raman peaks of GEN were observed in the spectrum 
of LLC-GEN, at around 1617, 1062, 991, 887 and 789 cm−1. For GEN, two characteristic 
peaks, centred at 1617 and 789 cm−1, were assigned to the vibration of the C = C bond in ring 
B and the C-C-C, C-C and C = O bonds in ring C of the isoflavonoid molecule. These bands, 
free from interference from LLC ingredient bands, were chosen to confirm the localization of 
GEN in the skin specimen. 
Raman spectra were acquired from skin treated with LLC-GEN and from non-treated 
intact ex vivo skin (Fig. 5), both perpendicular to the SC at equivalent depth (1000 µm). In the 
Raman spectrum of the treated skin, characteristic peaks of GEN and the LLC ingredients 
were observed at around 1670-1650 and 1470-1410 cm−1, respectively. The band of interest 
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Fig. 4. Experimental Raman spectra of Cremophor RH 40 (a), isopropyl myristate (b), LLC-
GEN composition (c) and pure GEN (d). 
Table 2. Observed Raman peaks and peak assignments of individual components and 
LLC-GEN (str = stretching, def = deformation, tw = twisting). 
Assignment Cremophor RH 40 
Isopropyl 
myristate LLC-GEN GEN 
str C = O (ester) 1734 1733 1733 -
str C = C (ring A) - - 1648 1648
str C = C (ring B) - - 1617 1617
def CH2-CH3 1442 1437 1440 -
str C = C - - - 1366
 - - - 1319
def CH2 and tw 
CH3 
1300 1300 1300 -
str C-C 1139 - - -
  1079 1076 -
str O-C 1063 1062 1063 1062
str C = C and C-
C-C (ring A) 
- - 991 991
str C = C (ring A) 
and C-C-C (ring 
C) 
- - 887 887
str C-CH 
(aromatic ring) 
843 - - -
 - 823 824 -
str C-C-C (C 
ring), str C = O 
- - 789 791
str C-C-C and C = 
C (ring A) 
- 601 596 596
str C-C-C (rings A 
and C) 
- - - 566
centred at 1440 cm−1 was assigned to the vibration of the amide functional group due to C = O 
stretching and –CH2, -CH3 bending of the skin lipid constituents. The C = C stretching 
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observed at 1617 cm−1 arose predominantly from the GEN isoflavonoid. The chemical 
mapping therefore confirmed the presence of the characteristic GEN band at around 1617 
cm−1. This peak is close to the vibrations of the native skin components. The skin component 
peaks at 1608 and 1453 cm−1 are well known to be associated with the C = C vibration of 
phenylalanine, the CH2 scissoring of lipids and the CH2, CH3 deformation of proteins in the 
native skin. 
 
Fig. 5. Raman spectra of GEN-treated skin (900 V, 2 min, 1000 µm depth) (a), non-treated skin 
specimen as control (1000 µm depth) (b), pure GEN (c) and GEN-free LLC composition (d) in 
the range 1900-1350 cm−1. 
Figure 6 displays qualitative distribution maps of the LLC components and GEN in animal 
skin specimens after different EP protocols, at 10-fold magnification. It was of interest to 
determine whether GEN diffusion is limited to the SC or to the epidermis or dermis. As 
discussed in the Materials and methods section, as the skin specimens were planar, there was 
no need for the z-axis and adjustment of the depth values. 1300 µm deep sections of the skin 
specimen were investigated, from corresponding top to bottom to the SC → epidermis → 
dermis. In order to confirm GEN diffusion, the chemical maps were resolved. The 
characteristic bands obtained for GEN at around 1617 cm−1 were used to visualize the spatial 
distribution of GEN from the Raman chemical mapping. The resolution of the chemical map 
and hence the identification of the ingredients present were achieved by using a multivariate 
curve resolution – alternating least squares chemometric method. This method furnishes the 
response profiles of different components in complex samples, and provides information 
about the composition. 
The presence of bands due to GEN and the LLC components in the upper layer of the skin 
(0-1000 µm) clearly indicates a good distribution following conventional treatment of the 
LLC-GEN composition (Fig. 6(a)). After the 900 V process for 1 min, GEN was accumulated 
in the middle section of the dermis (Fig. 6(b)). The penetration of GEN into the dermis was 
slowed by the dermis a being dense network of collagen fibres. The GEN and LLC 
component contents of the skin specimen (to a depth of 1300 µm) were relatively low after 
the 900 V EP process for 2 min (Fig. 6(c)), indicating that the GEN penetrated into the deep 
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layer of the dermis. Although the difference between the EP processes for 1 and 2 min may 
seem minor, the slower diffusion of GEN may be presumed because of the enrichment of the 
LLC components (as vehicles of GEN) in the 1000-1300 µm deep section. In the absence of 
the EP process, the epidermal and upper dermal regions serve as a tight barrier, impeding 
deep GEN delivery. Thus, slow diffusion of the GEN took place. 
 
Fig. 6. Qualitative Raman maps of GEN distribution in animal skin specimens following 
different EP protocols (at 10-fold magnification). Conventionally treated skin as control (a), 
skin treated with EP at 900 V for 1 min (b) and skin treated with EP at 900 V for 2 min (c). 
Image: LLC-GEN composition, CRH + IPM: Cremophor RH 40 + isopropyl myristate, GEN: 
Genistein. Colour coding of content: red>yellow>green>blue. 
4. Conclusions 
In summary, the results of this study have demonstrated that our newly developed LLC 
formulation is a suitable carrier for the poor water soluble GEN. The penetration through the 
skin was ensured already by LLC-GEN alone application. However the combination of LLC 
nanocarrier system with EP was resulted rapid and more effective transdermal drug transport 
than alone LLC-GEN formulation. The synergistic effect of EP was verified by both the ATR-
FTIR and the Raman spectroscopy. It could be concluded from our study that combination of 
LLC an EP process is very promising, but the optimization of drug penetration is necessary. 
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The aim of this study was to investigate the behavior of promising penetration enhancers through the
use of 2 different skin test systems. Hydrogel-based transdermal formulations were developed with
ibuprofen as a nonsteroidal anti-inﬂammatory drug. Transcutol and sucrose esters were used as
biocompatible penetration enhancers. The permeability measurements were performed with ex vivo
Franz diffusion cell methods and a newly developed Skin Parallel Artiﬁcial Membrane Permeability
Assays (PAMPA) model. Franz diffusion measurement is commonly used as a research tool in studies of
diffusion through synthetic membranes in vitro or penetration through ex vivo human skin, whereas Skin
PAMPA involves recently published artiﬁcial membrane-based technology for the fast prediction of skin
penetration. It is a 96-well plate-based model with optimized artiﬁcial membrane structure containing
free fatty acid, cholesterol, and synthetic ceramide analog compounds to mimic the stratum corneum
barrier function. Transdermal preparations containing 2.64% of different sucrose esters and/or Transcutol
and a constant (5%) of ibuprofen were investigated to determine the effects of these penetration en-
hancers. The study demonstrated the good correlation of the permeability data obtained through use of
human skin membrane and the in vitro Skin PAMPA system. The Skin PAMPA artiﬁcial membrane serves
as quick and relatively deep tool in the early stages of transdermal delivery systems, through which the
enhancing efﬁcacy of excipients can be screened so as to facilitate the choice of effective penetration
components.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
Transdermal drug delivery has received increased attention in
recent years thanks to its numerous advantages over the oral and
injection routes, such as avoidance of the hepatic “ﬁrst-pass”
metabolism, sustained drug delivery, protection of the gastroin-
testinal tract from drugs, and good patient compliance. The main
penetration barrier for most drugs is the stratum corneum (SC), the
outermost 10-15 mm thick zone of the epidermis. The SC consists of6-62-545-573; Fax: þ36-62-
nyi).
®. Published by Elsevier Inc. All rseveral layers of almost nonpermeable, nonviable corniﬁed cells
(corneocytes) and intercellular lipid domains. These lipids
comprise approximately 50% ceramides, 25% cholesterol, 15% free
fatty acids, and some minor components.1
The strategies most widely applied with the aim of improving
drug penetration involve the use of chemical penetration
enhancers and skin hydration.2 In this respect, we report here on
the development of hydrogel formulations containing penetration
enhancers for the transdermal delivery of ibuprofen (IBU), a
nonsteroidal anti-inﬂammatory drug frequently used for the
treatment of musculoskeletal injuries. The transdermal delivery of
IBU is a convenient way to minimize the potential risk of adverse
gastrointestinal events (e.g., bleeding, ulceration, and perforation
of the stomach).3 The physicochemical properties of IBU areights reserved.
B. Balazs et al. / Journal of Pharmaceutical Sciences xxx (2016) 1e72appropriate for its development as a transdermal gel formulation,4
but the use of a penetration enhancer is unescapable because of the
highly structured SC.1
Transcutol (TR) and sucrose fatty acid esters (SEs) were chosen
as penetration enhancer excipients. TR is a powerful solubilizing
agent and enhances the percutaneous penetration of various drugs,
especially when it is used in combination with suitable surfac-
tants.5,6 SEs, a new generation of nonionic surfactants, are likewise
favorable penetration enhancers.7 They have low toxicity, good
biocompatibility, and excellent biodegradability, and they cause
little dermatologic damage.8,9 The extent of the ability of the SEs to
promote drug release in vitro has been reported to depend on the
hydrophilic-lipophilic balance (HLB) value and the C atom number
of the fatty acid chain in the SEs.10 The effectiveness of SEs in
combination with TR has also been demonstrated in the experi-
ments on porcine ear skin and human skin.6,11
The efﬁcacy of a surfactant in enhancing transdermal delivery is
dependent on its structure, the physicochemical properties of the
drug, and the nature of the vehicle, the main factors deﬁning
the surfactanteskin interaction.12,13 Numerous studies have
demonstrated that SEs and TR interact with the skin.6,11,14,15 How-
ever, simple in vitro10 or ex vivo animal membrane diffusion
measurements16 are not sufﬁcient to allow an evaluation of the
penetration-enhancing effects of different SEs. The SC in animals
differs from the human SC in thickness, the number of corneocyte
layers, the hair density, the water content, the lipid proﬁle, and the
morphology.17 To select the best formulation for a clinical study, it is
important to investigate transdermal formulations with ex vivo
human skin penetration methods.
The transepidermal water loss (TEWL) is an indicator of the
integrity of the skin barrier, and measurement of the TEWL is an
easy and rapid noninvasive means of examining the effects of new
transdermal systems.18,19 For penetration investigations, measure-
ments were made across excised human epidermis with a vertical
Franz diffusion cell.20 Because the use of human skin in research
encounters ethical, health, and supply problems,17 our transdermal
gels were additionally tested in newly developed Skin Parallel
Artiﬁcial Membrane Permeability Assays (Skin PAMPA),21 devel-
oped as a rapid, reproducible, and cost-efﬁcient system for the
prediction of skin penetration. The Skin PAMPAwas designed to be
biomimetic, that is, the same or similar components have been
applied as present in the most important barrier of human skin. As
the main barrier of the human skin, it is known to be the outermost
layer of epidermis, the SC, Skin PAMPA has been designed to mimic
the features of this layer. SC composes of corneocytes embedded
into a multilamellar lipid layer. The lipid layer consists of a mixture
of ceramides, cholesterol, and free fatty acids as major components
and provides the main route of penetration, the paracellular
pathway. The Skin PAMPA membrane was created by using free
fatty acid, cholesterol, and a synthetic ceramide analog compound
(long-chain tartaric acid diamide derivative named certramide) to
mimic the features of ceramide in the lipid matrix.22,23 The opti-
mized artiﬁcial membrane mimics molecular transport through the
SC, and the commercially already available Skin PAMPATM system
can serve as a good alternative tool for penetration studies of
transdermal formulations.24
The aims of the present study were to compare different types
of SEs (alone or in combination with TR) from the aspect of their
ability to enhance the delivery of IBU through human skin and to
prove the usefulness of the Skin PAMPA model as a valuable tool in
research on transdermal systems. The Skin Pampa model has
never been used earlier to investigate transdermal penetration
enhancers but the use of it could offer such advantages as a simple
and cost-effective early phase screening system of penetration
enhancers.Materials and Methods
Sample Preparation
A penetration-enhancing free hydrogel (control gel) was
prepared by the following procedure. A 5 wt% IBU (Sigma-Aldrich,
St Louis, MO) was dissolved in polyethylene glycol 400 (20 wt%;
Hungaropharma Ltd., Budapest, Hungary) and this solution was
added to 3 wt% Carbopol 971 (Lubrizol Corporation/Azelis,
Budapest, Hungary) hydrogel prepared with distilled water. The
pH was adjusted to 7.0 by adding trolamine (7 wt%; Hungar-
opharma Ltd.). Sucrose esters, sucrose laurate D-1216 (SL), and
sucrose myristate C-1416 (SM) were purchased from Mitsubishi-
Kagaku Foods Corporation, Tokyo, Japan. To compare the 2 SEs,
2.64 wt% was incorporated in Carbopol 971-based hydrogel
(SL gel and SM gel). A 2.64 wt% was chosen because this gave
the maximum SE concentration-containing hydrogel which
did not require a centrifugation process to remove the bubbles.
Similar compositions were prepared by using 10wt% TR (Gattefosse
and Lubrizol Corporation/Azelis, Budapest, Hungary) (TR gel); 2.64
wt% SE þ 10% TR-containing gels too were prepared (SL þ TR and
SM þ TR gel).
TEWL Measurements
Measurements were performed under standardized conditions
(room temperature of 21C-23C and 40%-50% relative humidity).
Seven healthy female volunteers aged between 23 and 60 years
with no history of dermatologic diseases or allergy participated in
the experiment. Informed consent was obtained from all these
volunteers, and the study was approved by the local ethics com-
mittee (the Regional and Institutional Human Medical Biological
Research Ethics Committee at the University of Szeged). The vol-
unteers were asked not to apply any moisturizer or cosmetic
product for at least 24 h before the process. They were given 30min
to adapt to the measurement room conditions. During the experi-
ment, samples were applied to the dorsal region of the hand of all
the subjects. TEWL values were determined on the same area of the
skin before and after 30 and 150 min of the sample application. The
measured values were compared with the values detected on the
nontreated skin; the changes in TEWL were expressed in percent-
age.25-27 Measurements were performed with a Tewameter® TM
300 instrument (Courage and Khazaka Electronic GmbH, Cologne,
Germany).
Drug Diffusion and Penetration Investigations
Preparation of Heat-Separated Epidermis
Excised human skin was obtained during abdominal plastic
surgery on a Caucasian female patient (aged between 30 and 40
years). This was approved in advance by the Ethical Committee of
the Human Investigation Review Board at Albert Szent-Gy€orgyi
Clinical Centre, University of Szeged. The subcutaneous fat tissue
was separated from the outer skin layers after the excision, and
the skin was stored at 20C overnight. Then, after thorough
defrosting, membrane separation was achieved with a previously
reported method.28 Individual portions were immersed in water
at 60C for 90 s. After removal of the skin from the water, it was
placed SC side up on a ﬁlter paper, and the epidermis (comprising
the SC and the viable epidermis) was gently removed from the
underlying dermis with the use of forceps. The latter was discarded,
and the epidermal membrane was ﬂoated onto the surface of
phosphate buffer solution (pH ¼ 7.4) for at least 20 min and then
placed on a supporting Poraﬁl membrane (cellulose acetate, pore
diameter 0.45 mm).29,30
Figure 1. TEWL measurement after single application of 6 ibuprofen-free topical formulations: (a) 30 min and (b) 150 min after treatment with control gel, TR gel, SL gel, SL þ TR
gel, SM gel, and SM þ TR gel. Values are given as percentages referred to TEWL before treatments. The plots are medians with 25th and 75th percentiles.
Table 1
Penetration Parameters of Ibuprofen Through Human Epidermis After 16 h
Formulation Q (mg/cm2) J (mg/cm2/h) EF
Control gel 463.95 ± 110.50 42.72 e
TR gel 193.36 ± 87.13 14.23 0.33
SL gel 866.79 ± 320.42 67.93 1.59
SM gel 889.22 ± 348.09 54.28 1.27
SL þ TR gel 825.08 ± 384.67 54.38 1.27
SM þ TR gel 1527.19 ± 764.62 91.59 2.14
Q, cumulative amount of IBU penetrated per cm2 versus time plots, average values ±
SD, n ¼ 5; J, slope of the concentration versus time proﬁle in the receiver
compartment; EF, ﬂux of penetrant from the gel containing an enhancer divided by
the ﬂux of penetrant from the control gel without an enhancer.
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Membrane permeability studies were carried out with a vertical
Franz diffusion cell system (Hanson Microette TM Topical &
Transdermal Diffusion Cell System; Hanson Research Corporation,
Chatsworth, CA). The surface area for diffusionmeasured 1.767 cm2.
A stirring rate of 450 rpmwas used. The donor phase was 0.30 g of
sample, which was placed on the epidermis supported on the
cellulose acetate membrane (Poraﬁl; Machenerey-Nagel, Germany,
and Pall Life Sciences, Washington, NY). Phosphate buffer solution
(pH ¼ 7.4) was used as an acceptor phase.4 The receptor medium
temperature was maintained at 37 ± 0.5C throughout the exper-
iments to support the physiological skin temperature (32 ± 0.5C)
on the membrane in the Franz cell.31 Experiments were performed
for 16 h. Samples of 0.8 mL were taken from the acceptor phase by
the autosampler (Hanson Microette Autosampling System; Hanson
Research Co., Chatsworth, CA) and replaced with fresh receiving
medium. The absorbance of the IBU content was measured
with a UV spectrophotometer (Helios a Thermospectronic
UV-spectrophotometer v4.55, Unicam; Thermo Fisher Scientiﬁc,
Waltham, MA) at a wavelength of l ¼ 264 nm via a previously
obtained calibration plot. The concentration of IBU and the
measured absorbance correlated linearly. Five parallel measure-
ments were made of the amount of IBU that penetrated over a
period. Results were expressed as mean ± SD.
PAMPA Method
The Skin PAMPATM sandwiches and the stirring bars (P/N:
110211) were purchased from Pion Inc. (Billerica, MA). The UV
plates were from Greiner Bio-One GmbH (Kremsmünster, Austria;
UV-star micro plate, clear, ﬂat bottom, half area). Standard Britton-
Robinson buffers weremade in-house, and 0.2M sodium hydroxide
was used to adjust the pH to 7.4 to serve the acceptor solution. The
Skin PAMPATM sandwiches were used after an overnight hydration
(Hydration Solution, Pion Inc. P/N: 120706). The bottom part of the
original Skin PAMPATM sandwich was replaced with Formulation
Plate purchased from Pion Inc. (P/N:120806). Seventy microliters of
gel was transferred to the Formulation Plate. The top plate was
ﬁlled with 250 mL of fresh acceptor solution, and stirring bars were
applied in everywell to avoid the effect of the unstirredwater layer.
The Gut-BoxTM from Pion Inc. was used for stirring. The resultant
system was incubated at 32C. The acceptor solution was sampledafter 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16 hours of incubation.
After each individual incubation period, 150 mL from the acceptor
compartment was transferred to UV plates, and the transferred
volume of receiving medium was replaced with fresh acceptor
solution. UV absorption (230-500 nm) was measured with a Tecan
Inﬁnite M200 instrument driven by Magellan 6 software (Tecan
Group Ltd., M€annedorf, Switzerland). Calibration for the quantita-
tive analysis was performed with IBU as standard compound. The
calibration curve (Beer-Lambert law: A ¼ A1%1cm*c*l) was prepared
by using 8 dilutions in Britton-Robinson buffer of pH 7.4. The
absorptionmaximumwas found at 264 nm. The linearity rangewas
100-600 mg/mL; the speciﬁc absorbtivity (A1%1cm) was 10.872;
R2 ¼ 0.9986. Calibration plots were constructed by least-square
linear regression analysis. Five parallel measurements were per-
formed for all formulations prepared for this study.Dissolution Analysis
Penetration parameters were obtained from the cumulative
amount of IBU penetrated per cm2 versus time plots (Q). The
transdermal ﬂux (J) was calculated from the slope of the concen-
tration versus time proﬁle in the receiver compartment and
expressed in mg/cm2/h. For the linear regression analysis, the linear
range of the incubation period from 1 to 6 h was selected, and this
range was used to calculate the ﬂux data of the compounds.
The effectiveness of a penetration enhancer was determined
by comparing the ﬂux of IBU in the presence and the absence of
Figure 2. Ibuprofen penetration proﬁles of transdermal formulations (a) with the ex vivo Franz cell method, (b) the in vitro Skin PAMPA system, and (c) the correlations between the
amounts of drug penetrated through human skin and Skin PAMPA.
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Table 2
Penetration Parameters of Ibuprofen Through the Skin PAMPA Model After 16 h
Formulation Q (mg/cm2) J (mg/cm2/h) EF
Control gel 5204.95 ± 311.23 432.35 e
TR gel 4941.95 ± 966.97 329.95 0.76
SL gel 5642.38 ± 383.43 517.06 1.20
SM gel 5812.12 ± 150.72 512.81 1.19
SL þ TR gel 5616.67 ± 208.33 483.72 1.12
SM þ TR gel 6062.98 ± 121.23 563.1 1.30
Q, cumulative amount of IBU penetrated per cm2 versus time plots, average values ±
SD, n ¼ 5; J, slope of the concentration versus time proﬁle in the receiver
compartment; EF, ﬂux of penetrant from the gel containing an enhancer divided by
the ﬂux of penetrant from the control gel without an enhancer.
Figure 3. Ex vivo (human epidermis) and in vitro (Skin PAMPA) enhancement factors of
different formulations.
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(EF), which was calculated via the following equation.32
EF ¼ ðflux of penetrant from the gel containing an enhancerÞ=
ðflux of penetrant from the control gel without an enhancerÞ:
(1)
Statistics
Results are presented as means ± SD. Two-way ANOVA was
used to determine the statistical difference between the data for
the various preparations and the control gel; ** and *** indicate p
< 0.01 and p < 0.001. Statistical analysis was performed through
the use of GraphPad Prism software (Graph-Pad Software Inc., La
Jolla, CA).
Correlation
The correlation between Skin PAMPA model and human
epidermis was calculated by the following formula (Eq. 2):
R ¼
Pðx xÞðy yÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP ðx xÞ2P ðy yÞ2
q (2)
where R is the correlation, x and y denote the amount of penetrated
drug as a function of time t in case of human epidermis and the
SkinPAMPAmodel, respectively, and are the average values of x and y.
Results and Discussion
TEWL measurement is the most appropriate noninvasive model
with which to study the skin barrier function and the effects of
penetration enhancers. Application of the control formulation
leads to lower TEWL values than the level before treatment. Even
after 150 min, the skin was well protected and lastingly by the
control gel. This phenomenon can be seen in the cases of TR, SM,
and the combination SM þ TR. Treatment with SL or SL þ TR-
containing gels resulted in only slight increases of TEWL. The
changes were not statistically signiﬁcant as compared with the
control gel. The skin barrier structure remained basically unaltered
for all the tested formulations. Although TR and the SEs caused
minimal modiﬁcations in the SC barrier structure,6,15 these
hydrogel-based trandsdermal preparations protected the special
SC structure (Fig. 1).
The in vitro and in vivo skin permeability of IBU is improved by
the use of a hydrophilic vehicle alone,33 but it is increased even
more by the application of penetration enhancers such as SEs.15
Table 1 presents the penetration parameters of IBU through
excised human epidermis. The SE gels increased the IBU penetra-
tion through the skin as appreciably compared with the enhancer-
free control gel, but the TR gel did not enhance the IBU penetration.
TR is thought to give rise to its penetration-enhancing function by
increasing the solubility of the applied drug. However, TR has also
been observed to display an accumulation property by increasing
the skin accumulation of topically applied drugs without a
concomitant increase in transdermal penetration. TR causes the
swelling of intercellular SC lipids, and lipophilic drugs such as IBU
are trapped within the swollen SC lipids.34
As regard SEs, SL (C ¼ 12, HLB ¼ 16) and SM (C ¼ 14, HLB ¼ 16)
were selected because SEs with lower C numbers and higher HLB
values increase drug release more than SEs with longer fatty acids
and lower HLBs.10 SL has been reported to maximize the effect of a
surfactant on membrane permeability.35 SEs may act by disrupting
the ceramideecholesterol or cholesterolecholesterol interaction.Increase of the carbon chain length of the fatty acids results in their
molecular weights increasing, and their mobility within the skin
layers is also expected to decrease, which may explain their lower
penetration enhancement effect.16 Ex vivo ﬂuxes (representing the
absorption rate per unit area) reveal that SL induces faster IBU
release than does SM, whereas the amount of penetrated IBU after
16 h was higher in the case of the SM gel. The ex vivo drug release
behavior data indicated that SL was not a better penetration
enhancer for IBU than SM (Table 1).
In contrast with the application of TR alone, it has been reported
that its combination with SE resulted in facilitated surfactant ab-
sorption into the deeper layers of the SC. This synergistic
enhancement between SE and TR affects only the penetration
depth of the formulation and does not increase the amount of drug
that penetrates.11 The SM þ TR gel exhibited the best penetration
parameters (Table 1) and penetration proﬁle for IBU (Fig. 2a). The
SLþTR gel resulted in a lower penetration than that with the SL gel,
but the difference was not statistically signiﬁcant (Fig. 2a). A
possible reason for this phenomenon could be that the TR depot
effect predominated in the case of the SL þ TR gel because SL is not
able to cause so much lipid disruption. In contrast with SL, SM may
cause a greater extent of lipid alteration through its higher carbon
chain and this prevents the TR depot effect. Furthermore, SM in
combination with TR proved to penetrate the skin well, and there
was a marked increase in IBU release from the SM þ TR gel as
B. Balazs et al. / Journal of Pharmaceutical Sciences xxx (2016) 1e76compared with the control gel. The ex vivo statistical analysis
indicated that only the SM þ TR gel resulted in a signiﬁcantly (p <
0.001***) higher penetrated IBU amount relative to the control gel
after 7 h (Fig. 2a).
Table 2 presents the penetration data on the different trans-
dermal formulations tested with the Skin PAMPA system. Lower
SD and higher penetration data are observed with the PAMPA
model than with the Franz cell method, which may be caused by
the differences in the membrane structure in the 2 procedures.
However, the penetration proﬁles obtained with the Skin PAMPA
and ex vivo Franz cell methods were in good agreement in most
cases (Figs. 2a and 2b). The differences between the PAMPA and
Franz cell results clearly indicate the TR depot phenomena which
can not be observed through the synthetic membrane.36 The
decreased amount of IBU penetrated from the TR gel relative to the
control gel was statistically signiﬁcant after 3 h (p < 0.001***;
Fig. 2b). The penetration-enhancing effect of the SEs is clear.
Although SL rather hampers the penetration through the synthetic
membrane, it increases the penetration of IBU efﬁciently through
the Skin PAMPA or the human epidermis.36 The SM gel caused
only a slightly lower ﬂux than that with the SL gel, yielding a
signiﬁcantly higher penetration proﬁle as compared with the
control gel after 4 h (p < 0.01**) and as compared with the SL gel
after 7 h (p < 0.001***; Fig. 2b). The combination SL þ TR also
demonstrated a lower penetration proﬁle, as can be seen in the case
of the ex vivo result. The penetration proﬁle of IBU from the SM þ
TR gel showed the earliest signiﬁcantly increased diffused IBU
amount (p < 0.001**) after 3 h as compared with the control gel and
after 7 h as compared with the SM gel (Fig. 2b). The highest average
penetration proﬁle of IBU was seen with this gel. This result was
veriﬁed by both the Skin PAMPA and the Franz cell method.
The determination coefﬁcients (R2) of linear regression of the
correlation between the amount of IBU penetrated through the
human skin and the amount of IBU penetrated through the Skin
PAMPA indicated a good correlation. The determination coefﬁcients
between the in vitro PAMPA and the ex vivo Franz cell methodswere
in the range 0.88-0.99 (Fig. 2c). These EF values observed with the
ex vivo and in vitromethods were of the same order of magnitude in
all 5 cases (Fig. 3).Conclusions
In summary, the results of this study have demonstrated that
the in vitro Skin PAMPA system is a convenient rapid method for
investigations of penetration enhancers to select the best one for
ex vivo human skin and in vivo animal studies. The ﬁndings with the
new artiﬁcial PAMPA membrane correlated closely with those with
an ex vivo human skin membrane. It can serve as an effective pre-
diction model for the monitoring of penetration enhancers and of
drug penetration through the skin. From this aspect, this method
could be the ﬁrst, rapid, cost-effective, and simple system with
which to test transdermal formulations. However, a better under-
standing of the penetration-enhancing effects of excipients neces-
sitates the application of both ex vivo and in vitro methods. Our
results indicate that TR as cosolvent with SM signiﬁcantly improved
the penetration of the surfactant into the skin and promoted
attainment of the maximum penetration effect. SM þ TR could be a
potential nontoxic biocompatible penetration enhancer combina-
tion for IBU in transdermal delivery systems.Acknowledgments
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